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“The aim of medicine is to prevent disease and prolong life, 
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Alcohol consumption is one of the leading global health hazards that can result in 
premature death and disability. However, moderate alcohol consumption is associated 
with a decreased risk of coronary heart disease (CHD). The association between alcohol 
and microvascular disease entities is less studied and largely unclear. Smoking is a well-
recognized risk factor for cancer, pulmonary disease, and cardiovascular disease (CVD). 
Previous epidemiological research has brought insight regarding the effect of both the 
magnitude and duration of smoking exposure on the development of vascular 
complications. In many countries with a high socio-demographic index, including 
Finland, the prevalence of smoking has decreased dramatically during the last decades, 
and the amount of people with a background of smoking exposure has increased. 
Therefore, it is relevant to explore not only the effect of active smoking but also the 
effect of smoking cessation on the development of vascular disease. People with type 
1 diabetes are at increased risk of cardiovascular complications compared with the 
general population due to their metabolic disease. Therefore, it is extremely important 
to identify other cardiovascular risk factors in people with type 1 diabetes, to prevent 
further morbidity. Previous studies have linked smoking with an increased risk of micro- 
and macrovascular complications in people with type 1 diabetes. However, these 
studies have often combined current and former smokers and neglect the effect of 
smoking cessation. In addition, most previous studies have not included dose-
dependent measures of smoking. 
  
Aims 
The aim of this thesis was to study the effect of alcohol consumption on the risk of 
diabetic nephropathy and severe diabetic retinopathy in people with type 1 diabetes. 
The effect of smoking on the development of diabetic nephropathy, CHD, and stroke 
was also addressed. In addition, the combined effect of smoking and a known genetic 
variant on the development of the end-stage renal disease (ESRD) was investigated. 
 
Subjects and methods 
All people included in the study were participants in the ongoing nationwide, 
multicenter Finnish Diabetic Nephropathy Study (FinnDiane), the aim of which is to 
identify the clinical, environmental, and genetic risk factors of micro- and 
macrovascular complications in people with type 1 diabetes. This thesis is based on four 
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studies. Study I (n=3608) is cross-sectional in nature and Study II (n=3613), Study III 
(n=2621), and Study IV (n=4506) are prospective. Information regarding micro- and 
macrovascular complications is based on data from FinnDiane visits and national data 
from the Finnish Care Register for Health Care and the Cause of Death Register. 
 
Results 
Compared with light consumers (<7 doses per week for men and <5 doses per week for 
women), people who had never consumed alcohol had a higher risk of both diabetic 
nephropathy and severe diabetic retinopathy. People who had given up using alcohol 
had the highest risk of diabetic nephropathy and retinopathy. The risk of diabetic 
nephropathy was increased in spirit-drinking men, and the risk of severe diabetic 
retinopathy was increased in all spirit drinkers compared with wine drinkers. Compared 
with never smokers, current smokers had a higher risk of diabetic nephropathy, both 
macroalbuminuria and ESRD. Former smokers had a similar risk of macroalbuminuria 
and ESRD compared with never smokers. In current smokers, the risk of diabetic 
nephropathy increased with increasing cumulative smoking, measured by pack-years. 
Compared with never smokers, current smokers had an increased risk of CHD, heart 
failure, and stroke, and former smokers had an increased risk of heart failure in the 
whole study population and an increased risk of stroke in men. In both current and 
former smokers, the risk of each cardiovascular event increased with increasing 
cumulative smoking measured in pack-years and increasing intensity of smoking 
measured in packs per day. The rare variant of allele rs4972593, previously known to 
increase the risk of ESRD in women, was associated with a decreased risk of ESRD in 
non-smoking men. In women, the increased risk of ESRD associated with the rare allele 
was equivalent to the risk seen in smoking women without the allele.  
       
Conclusions 
Abstaining from alcohol or previous alcohol consumption and the consumption of 
spirits are associated with a higher risk of diabetic nephropathy and severe retinopathy. 
Current smoking is associated with a higher risk of diabetic nephropathy, CHD, heart 
failure and stroke in a dose-dependent manner. After smoking cessation, the risk of 
diabetic nephropathy and CHD is decreased and approaches the risk seen in never 
smokers. However, the risk of heart failure and stroke remains higher in former 
smokers, especially in those who have smoked longer and with greater intensity. 
Contrary to the previous findings in women, the rare allele rs4972593 seems to have a 






Maailmanlaajuisesti alkoholi on tärkeimpiä ennenaikaisen kuoleman ja 
työkyvyttömyyden aiheuttajia. Kohtuullisella alkoholin käytöllä on kuitenkin todettu 
myös sepelvaltimotaudilta suojaava vaikutus. Alkoholinkäytön vaikutus pienten 
verisuonten tauteihin, kuten diabeettiseen silmänpohjatautiin ja munuaistautiin on 
vielä pitkälti selvittämättä. Tupakoinnin on osoitettu lisäävän riskiä sairastua erilaisiin 
syöpiin, keuhkosairauksiin ja sydän- ja verisuonitauteihin. Aikaisemmat 
epidemiologiset tutkimukset ovat osoittaneet tupakoinnin määrän ja keston 
vaikuttavan verisuonisairauksien kehittymiseen. Monissa kehittyneissä maissa, kuten 
Suomessa, tupakointi on vähentynyt huomattavasti viimeisten vuosikymmenten 
aikana, mikä on myös johtanut suurempaan aiemmin tupakoinnille altistuneiden 
henkilöiden joukkoon. Siispä onkin tärkeää tutkia aktiivisen tupakoinnin vaikutusten 
ohella myös aiemman tupakka-altistuksen vaikutusta verisuonisairauksien 
kehittymisessä. Tyypin 1 diabetes, eli insuliininpuutosdiabetes, lisää jo itsessään sydän- 
ja verisuonitautien riskiä. Tämän vuoksi onkin ensisijaisen tärkeää kartoittaa muita 
sydän- ja verisuonitautien riskitekijöitä tyypin 1 diabeetikoilla. Aiemmat tutkimukset 
ovat osoittaneet, että tupakointi lisää riskiä sairastua diabeteksen lisäsairauksiin. Nämä 
tutkimukset ovat kuitenkin usein jättäneet selvittämättä tupakoinnin lopetuksen ja 
tupakoinnin määrän ja keston osallisuuden diabeteksen lisäsairauksien kehittymisessä. 
 
Tavoitteet 
Väitöskirjan tavoitteena oli tarkastella alkoholinkäytön ja eri juomalaatujen vaikutusta 
diabeettisen silmänpohjasairauden ja munuaistaudin riskiin tyypin 1 diabeetikoilla. 
Lisäksi tutkittiin tupakoinnin vaikutusta diabeettisen munuaistaudin, sepelvaltimo-
taudin, sydämen vajaatoiminnan ja aivotapahtuman ilmaantuvuuteen. Tavoitteena oli 
myös tarkastella tupakoinnin ja aiemmin löydetyn loppuvaiheen diabeettisen 
munuaistaudin riskiin liitetyn geenivariantin yhteisvaikutusta.  
 
Tutkimusaineisto ja menetelmät 
Tutkimus on osa FinnDiane (Finnish Diabetic Nephropathy Study) tutkimusta, joka on 
yhä käynnissä oleva koko Suomen kattava monikeskustutkimus, jonka päämääränä on 
kartoittaa kliinisiä, geneettisiä ja elintapoihin ja ympäristötekijöihin liittyviä 
lisäsairauksien riskitekijöitä tyypin 1 diabeetikoilla. Väitöskirja koostuu neljästä 
osatyöstä. Osatyö I on poikkileikkaustutkimus (n=3608) ja osatyöt II (n=3613), III 
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(n=2621) ja IV (n=4506) ovat luonteeltaan seurantatutkimuksia. Tiedot lisäsairauksien 
kehittymisestä saatiin yhdistämällä FinnDiane-aineisto valtakunnalliseen sosiaali- ja 
terveydenhuollon hoitoilmoitusjärjestelmään ja kuolinsyyrekisteriin. 
 
Tulokset 
Henkilöillä, jotka eivät koskaan olleet käyttäneet alkoholia, oli suurempi vaikean 
diabeettisen silmänpohjataudin ja munuaistaudin riski verrattuna alkoholia kohtalaisen 
vähän käyttäviin (miehet alle <7 ja naiset <5 annosta per viikko).  Suurin silmänpohja- 
ja munuaistaudin riski oli henkilöillä, jotka olivat lopettaneet alkoholin käytön. 
Väkevien alkoholijuomien käyttöön liittyi kohonnut vaikean silmänpohjataudin riski 
viininjuontiin verrattuna koko tutkimusaineistossa ja miehillä myös kohonnut 
munuaistaudin riski. Tupakoimattomiin verrattuna nykyinen tupakointi lisäsi 
diabeettisen munuaistaudin riskiä, mitattuna sekä makroalbuminurialla että 
loppuvaiheen munuaistaudilla. Tupakoinnin lopettaneilla diabeettisen munuaistaudin 
etenemisen riski oli samaa tasoa kuin tupakoimattomilla. Myös suurempi tupakoinnin 
määrä ja altistuksen kesto askivuosina mitattuna liittyi lisääntyneeseen munuaistaudin 
etenemisen riskiin. Tupakointi lisäsi myös sepelvaltimotaudin, sydämen 
vajaatoiminnan ja aivotapahtumien riskiä, joka oli sitä suurempi, mitä suurempi oli 
tupakoinnin aiempi altistus (askivuodet) ja päivittäisen tupakoinnin määrä (aski/vrk). 
Tupakoinnin lopettaneilla havaittiin suurentunut riski sairastua sydämen 
vajaatoimintaan ja aivotapahtumiin. Aiemmassa tutkimuksessa löydetty loppuvaiheen 
munuaistaudin riskiä naisilla lisäävä geenivariantti rs4972593 vähensi loppuvaiheen 
munuaistautia tupakoimattomilla miehillä. Naisilla kyseinen geenivariantti aiheutti 
tupakointiin verrattavan kasvun loppuvaiheen munuaistaudin riskiin. 
 
Johtopäätökset 
Alkoholiabstinenssi, aiempi alkoholinkäyttö ja väkevien juomien kulutus lisää 
diabeettisen silmänpohjataudin ja munuaistaudin riskiä tyypin 1 diabeetikoilla. 
Tupakointi lisää riskiä sairastua diabeettiseen munuaistautiin, sepelvaltimotautiin, 
sydämen vajaatoimintaan ja aivotapahtumiin. Riski lisääntyy askivuosien ja 
päivittäisten savukkeiden määrän kasvaessa. Tupakoinnin lopettaneilla diabeettisen 
munuaistaudin ja sepelvaltimotaudin riski lähestyy tupakoimattomien riskiä, mutta 
sydämen vajaatoiminnan ja aivotapahtumien riski säilyy korkeampana 
tupakoimattomiin verrattuna. Toisin kuin naisilla rs4972593 geenivariantti vaikuttaisi 





Smoking is a major global health hazard, accounting for 7.1 million attributable deaths 
and 218 million disability-adjusted life years yearly (1). The four leading causes of death 
attributable to smoking are ischemic heart disease (1.62 million), chronic obstructive 
pulmonary disease (1.23 million), respiratory tract malignancies (1.19 million), and 
stroke (887 000). Among CVDs, the risk of non-fatal myocardial infarction, heart failure 
or stroke is 2–3 times higher in current smokers (2-4). During the last decades, the 
prevalence of smoking has declined in countries with a high socio-demographic index. 
Based on statistics from the Finnish Institute for Health and Welfare, during 2005–2018 
the prevalence of current smokers in Finland declined from 30% to 15% in men and 
from 18% to 13% in women (5). Despite the decline in smoking prevalence, 8% of all 
vascular deaths and 8.5% of all deaths in Finland are still estimated to be attributable 
to smoking (6). 
In people with type 1 diabetes, the majority of excess morbidity and mortality is due to 
micro- and macrovascular complications. The effect of smoking on vascular 
complications has been extensively studied in the general population and to some 
extent in people with type 2 diabetes. However, data regarding the effect of smoking 
on different vascular complications in people with type 1 diabetes is limited. In 
particular, more precise data—including dose-dependent measurements of smoking 
and data regarding the effect of smoking cessation on micro- and macrovascular 
complications—are lacking for people with type 1 diabetes.  
Unlike the prevalence of smoking, current alcohol consumption has increased during 
the last decades in high socio-demographic index countries and particularly among 
women. Globally, 39% of men and 25% of women are current drinkers, but the 
difference in alcohol consumption between men and women varies between countries, 
and the disparity is lowest in high socio-demographic index countries (7). Based on a 
Finnish national survey from 2016, up to 88% of men and 85% of women in Finland are 
current drinkers (8). 
Globally, 2.8 million deaths are attributed to alcohol consumption, and alcohol is the 
seventh leading risk factor for premature death and disability (7). In Finland, the 
number of deaths related directly to alcohol (alcohol psychosis, dependence, poisoning 
or, liver disease) is the highest among the Nordic countries. In 2015, 42.8 deaths per 
100 000 capita were directly attributable to alcohol consumption in Finland compared 
with only 8.9 deaths per 100 000 capita in Sweden (9). The association between alcohol 
consumption and the risk of different disease entities is complex and depends on the 
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amount of alcohol consumed. In addition to the harmful effects, there is evidence of a 
beneficial effect of light-to-moderate alcohol consumption on some ischemic CVD 
entities and type 2 diabetes. The effect of alcohol consumption on microvascular 
disease entities is less studied. In particular, the effect in people with type 1 diabetes 
remains unclear.  
Given the major health impact of cigarette smoking and alcohol consumption and the 
lack of data regarding the association between these behavioral risk factors and 
vascular complications in people with type 1 diabetes, the aim of this series of studies 
was to evaluate the effect of alcohol consumption and smoking on micro- and 




















2 REVIEW OF THE LITERATURE 
 
2.1 Diagnosis and classification of diabetes 
 
2.1.1 Diagnostic criteria for diabetes 
 
Diabetes mellitus is a group of metabolic disorders characterized by chronic 
hyperglycemia caused by defects in insulin secretion, insulin action, or both. According 
to the World Health Organization (WHO) criteria, diabetes is diagnosed if fasting blood 
glucose is higher than 7.0 mmol/l in repeated measurements, if any blood glucose value 
is 11.1 mmol/l or higher with symptoms of hyperglycemia, if the 2-h oral glucose-
tolerance test is abnormal (≥11.1 mmol/l), or if glycated hemoglobin A1c (HbA1c) is 48 
mmol/mol (6.5%) or higher (10, 11). The criteria for intermediate hyperglycemia 
(prediabetes) include impaired glucose tolerance and impaired fasting glucose. 
Impaired glucose tolerance is diagnosed when fasting plasma glucose is <7.0 mmol/l 
but the 2-h plasma glucose in an oral glucose tolerance test is ≥7.8 mmol/l and <11.1 
mmol/l. Impaired fasting glucose is diagnosed when fasting plasma glucose is above 
the normal range (6.1–6.9 mmol/l), but the 2-h plasma glucose in an oral glucose 
tolerance test is normal (<7.8 mmol/l).  
  
2.1.2 Classification of diabetes 
 
According to the American Diabetes Association (ADA) position statement, diabetes is 
classified into four different categories: type 1, type 2, gestational, and other specific 
types of diabetes (12). Classification is based on the combination of patient 
characteristics, such as age and body mass index (BMI), the presence of hyperglycemia 
symptoms (polyuria and weight loss), and specific laboratory tests for autoantibodies 






2.1.3 Type 1 diabetes 
 
Type 1 diabetes accounts for 5–10% of all cases of diabetes. It is an autoimmune disease 
often diagnosed in children and young adults but can also manifest in older age. Due to 
genetic susceptibility and environmental triggers, such as viral infections, childhood 
obesity, or dietary factors, autoantibodies are formed against the insulin-producing β-
cells in the pancreas. This immunological process leads to β-cell destruction and gradual 
cessation of insulin production and eventually the need for lifelong insulin replacement 
therapy (13). Type 1 diabetes is often diagnosed due to milder symptoms caused by 
hyperglycemia, such as polydipsia, polyuria, and weight loss. But sometimes 
ketoacidosis, which requires treatment in the intensive care unit, is the first 
manifestation of the disease. The autoantibodies, such as glutamic acid decarboxylase, 
islet antigen 2, and insulin antibodies, can be detected months or even years before 
the diagnosis, and when hyperglycemia is detected, autoantibodies are found in 85–
90% of patients (14). During the last decades, the incidence of type 1 diabetes has 
increased globally, probably due to an increased prevalence of childhood obesity and 
environmental determinants, such as improved hygiene associated with a decline in 
infectious diseases and changes in gut microbiota (15-18). In Finland, the incidence rate 
of type 1 diabetes is the highest in the world at around 55 per 100 000 person-years in 
children younger than 15 years. This is 50% higher compared with Sweden, where the 
incidence is the second highest in Europe (19-21). However, in Finland the incidence of 
type 1 diabetes reached a plateau between 2006 and 2011 and after that the incidence 
has declined especially in the youngest children, being around 40 per 100 000 person-
years in children aged less than five (22). 
 
2.1.4 Type 2 diabetes 
 
Type 2 diabetes is the most common form of diabetes, accounting for 90–95% of all 
cases with diabetes. Type 2 diabetes is a metabolic disorder; instead of an absolute lack 
of insulin, the key components are insulin resistance and relative insulin deficiency. 
While type 1 diabetes is a disease of the pancreas, type 2 diabetes is associated with 
pathophysiological defects also in the liver, skeletal muscle, adipose tissue, kidneys, 
brain, and small intestine (23). Lifestyle-associated environmental risk factors play a 
crucial role in the development of type 2 diabetes, which is strongly associated with 
metabolic syndrome, obesity, and lack of physical activity. Type 2 diabetes is also highly 
heritable, particularly in those with age at onset of 35–60 (24). Large genome-wide 
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association studies (GWAS) and more recent exome sequencing studies have identified 
more than 400 genetic variants associated with the risk of type 2 diabetes (25, 26). 
Most are common variants with very small effects; therefore, combined polygenic risk 
scores have been generated to predict type 2 diabetes (27). Globally, over 460 million 
people have been diagnosed with type 2 diabetes, and in Finland the prevalence is 
estimated to be around 500 000 (28, 29). 
   
2.1.5 Gestational diabetes and other specific types of diabetes 
 
Based on the ADA criteria, diabetes is considered gestational if the diagnosis is made 
during the second or third trimester of pregnancy. If diabetes is diagnosed during the 
first trimester, it should be classified as pre-existing pregestational diabetes (most 
often type 2 diabetes). If gestational diabetes or prediabetes is diagnosed during 
pregnancy, special emphasis should be placed on changing one’s lifestyle to minimize 
the risk of developing type 2 diabetes in the future.  
The fourth category of diabetes is caused by other specific causes. These are 
monogenetic defects in β-cell function, including neonatal diabetes and different types 
of maturity-onset diabetes of the young. Different diseases affecting the exocrine 
pancreas can also cause diabetes, such as pancreatitis, cystic fibrosis, trauma, and 
pancreatic carcinoma. Some drugs, such as glucocorticoids, can also induce diabetes, 
particularly in people with pre-existing intermediate hyperglycemia (prediabetes) (12). 
 
2.1.6 Novel methods for diabetes classification 
 
Diabetes is a heterogeneous disease and despite modern diagnostic methods 
misclassification may still occur due to overlapping characteristics of different types of 
diabetes. In addition, especially for type 2 diabetes, the clinical presentation and 
prognosis of the disease varies between individuals. Therefore, novel cluster analyses 
based on clinical variables and genetic variants have been developed to stratify 
subclasses of diabetes (30, 31). Hopefully, this deeper knowledge of the nature of 
diabetes will help identify the patients who are at the highest risk of developing 
diabetes complications and will eventually lead to individually optimized treatment 




2.2 Macrovascular complications in type 1 diabetes 
 
2.2.1 Cardiovascular disease 
 
CVD comprises different diseases of the heart and the circulatory system that often 
have an atherosclerotic etiology. Clinically, the two major CVD disease phenotypes are 
CHD or coronary artery disease and stroke (ischemic or hemorrhagic). Other important 
CVD diagnoses are heart failure and peripheral artery disease. CVD is the leading cause 
of death, accounting for 31.5% of all deaths globally and 45% of all deaths in Europe 
(34). Globally, CVD mortality increased 14.5% from 2006 to 2016 (35). However, in most 
European countries the CVD mortality has decreased since 2003. In Europe, CHD 
accounts for 20% of all deaths, stroke accounts for 11%, and the other forms of CVD 
account for 14%. The prevalence of self-reported CVD is 9.2% in Europe and 11.9% in 
Finland (34). 
     
2.2.1.1 Coronary heart disease 
 
CHD is caused by atherosclerosis of the coronary arteries leading to clinical phenotypes 
that range from exercise-induced angina pectoris to acute myocardial infarction, 
depending on the severity of the disease. CHD is the leading cause of all health loss 
globally, measured by mortality and disability-adjusted life years (36). In Finland, the 
prevalence of CHD in people aged 50 and over is 14.3% in men and 7.1% in women (37). 
In people with type 1 diabetes, the risk of CHD is about 10 times higher compared with 
the general population, but the relative risk can be up to 20–30 times higher depending 
on age, sex, age at onset of diabetes, and the presence of diabetic kidney disease (38-
40).  
 
2.2.1.2 Heart failure 
 
Instead of a single disease, heart failure is defined as a “clinical syndrome that results 
from any structural or functional cardiac disorder that impairs the ability of the 
ventricle to fill or eject blood”. Depending on the left ventricular systolic function, heart 
failure can be divided into two categories: heart failure with preserved ejection fraction 
and heart failure with reduced ejection fraction (41). CHD is the most common cause 
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of heart failure, either alone or in combination with hypertension. Other etiological 
causes are valvular diseases (e.g., sclerosis of the aortic valve), different 
cardiomyopathies, cardiac arrhythmias (e.g., atrial fibrillation), or more seldom 
inflammatory or infectious diseases (pericarditis or myocarditis) (42). Heart failure is 
uncommon in younger age groups, but the prevalence increases with increasing age. In 
Finland, the prevalence of heart failure is 5.3% in men and 2.5% in women aged 60–69, 
but in people 80 years and older, the prevalence is 23.7% in men and 27.3.% in women 
(37). Diabetes is associated with an increased risk of heart failure and people with type 
1 diabetes have a 4-fold risk of hospitalization due to heart failure compared with the 




According to the WHO, stroke is defined as “rapidly developed clinical signs of focal (or 
global) disturbance of cerebral function, lasting more than 24 hours or leading to death, 
with no apparent other cause than vascular origin” (44). The etiology of stroke can be 
ischemic (cerebral infarction) or hemorrhagic (intracranial hemorrhage or 
subarachnoid hemorrhage). Globally, stroke is the second leading cause of death after 
CHD, causing 5.5 million deaths in 2016 (45). Stroke is also the second leading cause of 
disability, causing 116.4 million disability-adjusted life years globally. In Finland, the 
prevalence of stroke in people aged 50 and older  is 6.6% in men and 6.1% in women 
(37). In people with type 1 diabetes, the risk of stroke is 5-fold higher compared with 
the general population (40, 46). 
     
2.2.1.4 Peripheral artery disease 
 
Peripheral artery disease is caused by atherosclerosis of the lower limb arteries, leading 
to impaired blood flow and eventually ischemic symptoms in the lower limbs. However, 
most affected patients are symptomless (diagnosed by ankle brachial index), and the 
characteristic claudication symptoms induced by exercise are rare compared with 
diffuse atypical leg symptoms (47). Only the most severe forms of peripheral artery 
disease lead to ulceration, gangrene, or even amputation. Peripheral artery disease, 
even asymptomatic, is associated with an approximately 3-fold increased risk of other 
CVD events and CVD mortality (48). In high-income countries, the prevalence of 
peripheral artery disease is around 6% in people aged 45–55, but up to 15–20% in 
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people aged 80–90 (49). In a study with a relatively young (mean age of 36) cohort of 
asymptomatic people with type 1 diabetes, the prevalence of peripheral artery disease 
was 12.8% (50). Based on a Swedish register study of type 1 diabetes, the cumulative 
risk of the most severe form of peripheral artery disease, lower-extremity amputation, 
was 11.0% in women and 20.7% in men by the age of 65 (51). 
 
2.3 Microvascular complications in type 1 diabetes 
 
2.3.1 Diabetic nephropathy (diabetic kidney disease) 
 
Diabetic nephropathy or diabetic kidney disease is identified clinically by persistently 
increased urinary albumin excretion (albuminuria) and/or sustained reduction in 
kidney function measured by an estimated glomerular filtration rate (eGFR) below 60 
ml/min per 1.73 m2 (52). Albuminuria is assessed using timed overnight or 24-h urine 
collections or estimated based on the urinary albumin-to-creatinine ratio in spot urine 
samples. The different categories of albuminuria are presented in Table 1. The 
nomenclature has changed since the 2012 Kidney Disease: Improving Global Outcomes 
guideline on chronic kidney disease, and microalbuminuria and macroalbuminuria have 
been replaced by moderately and severely increased albuminuria (53). Many 
conditions, such as infection, fever, exercise, menstruation, hyperglycemia, and 
hypertension can transiently elevate the urinary albumin excretion rate (UAER). 
Therefore, the albuminuria level should be confirmed with two additional 
measurements during a 3–6-month period before a diagnosis of increased albuminuria 
can be made. 
Table 1. Albuminuria categories in chronic kidney disease 
Category 







Timed 24-h urine collection <30 mg/24 h 30–300 mg/24 h >300 mg/24 h 
Timed overnight urine collection <20 µg/min 20–200 µg/min >200 µg/min 
Spot urine albumin-to-creatinine 
ratio 





Kidney function is measured by the glomerular filtration rate that can be estimated by 
calculation from the plasma creatinine concentration (54). There are five different 
categories of chronic kidney disease based on the progressive decrease in the GFR level 
(Table 2) (53, 55).  
 
Table 2. GFR categories in chronic kidney disease 

















(mL/min/1.73 m2)  
≥90 60–89 45–59 30–44 15–29 <15 
CKD: chronic kidney disease 
 
Microalbuminuria is the first sign of diabetic nephropathy and is often combined with 
elevated blood pressure and prevalent diabetic retinopathy. Before modern treatment 
options, the natural course of diabetic nephropathy was devastating, and after the 
onset of proteinuria (macroalbuminuria) kidney function declined in a progressive 
manner and mean life expectancy was less than five years (56). However, more recent 
studies have shown that albuminuria is a dynamic process, and in up to 40% of 
microalbuminuria cases UAER could regress back to the normal range (57).  
Albuminuria can exist alone or in combination with a reduced eGFR level. However, in 
the final stage of diabetic nephropathy, ESRD, kidney function is severely impaired, and 
by definition dialysis treatment has been initiated or the patient has received a renal 
transplant. Diabetic nephropathy is the leading cause of ESRD worldwide as well as in 
Finland (28, 58, 59). Based on the Finnish Registry for Kidney Diseases, in 2017, active 
kidney replacement therapy (dialysis or kidney transplant) was initiated for 190 people 
with diabetes (106 with type 1 and 84 with type 2), which accounted for 35% of all new 
kidney replacement therapies (59). 
The prevalence of diabetic nephropathy after 20 years of diabetes duration has 
decreased from 30% to 14% during the last decades, mostly due to improved glycemia 
and blood pressure care (60). Based on a recent Finnish study, the cumulative risk of 
ESRD was 7% after 30 years’ duration of diabetes, but the relative risk was significantly 
lower in patients diagnosed after 1995 compared with those diagnosed before 1980 
(61).    
23 
 
Based on ADA recommendations, screening for diabetic nephropathy should occur 
yearly by measuring urinary albumin and eGFR levels in all people with type 1 diabetes 
who have a duration of diabetes of ≥5 years (62). Optimizing blood pressure and 
glucose control is essential to reduce the risk of diabetic kidney disease and based on 
the Kidney Disease: Improving Global Outcomes guidelines treatment with angiotensin-
converting-enzyme inhibitor or with an angiotensin II receptor blocker is recommended 
for all people with diabetes and hypertension. In people with type 2 diabetes, 
sodium/glucose co-transporter 2 (SGLT2) inhibitor is recommended to optimize 
glycemic control due to the beneficial effects on kidney function and CVD risk (63). In 
people with type 1 diabetes, SGLT2 inhibitors are also shown to have beneficial effects 
on glycemia, blood pressure, body weight, and albuminuria (64, 65).  
 
2.3.2 Diabetic retinopathy 
 
The diagnosis of diabetic retinopathy is based on fundus photographs, and retinal 
screening is recommended for people with type 1 diabetes 5 years after the onset of 
diabetes and every 1–2 years after that. Diabetic retinopathy is classified into four 
different stages based on the severity of the vascular changes in the retina—mild 
nonproliferative, moderate nonproliferative, severe nonproliferative, and proliferative 
diabetic retinopathy (66, 67). Macular edema, retinal thickening in the macular area 
due to the leakage from damaged capillaries, can occur at any stage of diabetic 
retinopathy and can lead to central vision loss if untreated (68). Diabetic retinopathy 
and diabetic macular edema are the leading causes of blindness among people of 
working age in developed countries. Based on a large pooled analysis of diabetes 
studies, after 20 years of diabetes duration the prevalence of  proliferative diabetic 
retinopathy is 40.4%, and the prevalence of macular edema is 17.3% in people with 
type 1 diabetes (69). 
The treatment of risk factors (hyperglycemia, hypertension, and hyperlipidemia) is 
crucial in preventing the initial changes in the retina and in delaying the progression of 
the early forms of retinopathy. However, there are also specific treatment options for 
the more severe forms of retinopathy. Laser photocoagulation has been used for 
decades and has been shown to reduce the risk of vision loss in patients with 
proliferative diabetic retinopathy and clinically significant diabetic macular edema (66). 
Advanced active proliferative diabetic retinopathy can also be treated by vitrectomy, a 
surgical procedure including incisions in the mid-part of the sclera anterior to the retina 
(68). Pharmacological treatment with anti-vascular endothelial growth factor agents 
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that prevent retinal neovascularization is recommended for central-involved macular 
edema and can also be used for proliferative diabetic retinopathy either in addition to 
photocoagulation or as a monotherapy (62).  
           
2.3.3 Diabetic neuropathy 
 
Diabetic neuropathy can be divided into three classes with multiple subgroups. Diffuse 
neuropathy includes distal symmetrical polyneuropathy and autonomic neuropathy 
(e.g., cardiac, gastrointestinal, and urogenital neuropathy). The other two classes of 
diabetic neuropathy are mononeuropathy and radiculopathy or polyradiculopathy (70). 
Distal symmetrical polyneuropathy and cardiac autonomic neuropathy are most 
studied, and after 20 years of diabetes duration the prevalence of distal symmetrical 
polyneuropathy and cardiac autonomic neuropathy is  approximately 25–30% in people 
with type 1 diabetes (71).  
Distal symmetrical polyneuropathy, in addition to peripheral artery disease, is an 
important cause of foot ulceration that can lead to lower-limb amputations. Therefore, 
annual foot screening, including evaluating the loss of protective sensation with 
monofilament testing, is recommended for all people with diabetes (62). 
Pharmacotherapeutic treatment options for diabetic neuropathy are mostly targeted 
on neuropathic pain, while the treatment options for other forms of neuropathy are 
limited (72). However, the electrophysiological abnormalities in nerve conduction 











2.4 Risk factors for vascular complications and atherosclerosis in type 1 
diabetes 
 
Risk factors for vascular complications can be categorized based on the mechanisms 
leading to either increased or decreased risk of different vascular complications. In 
addition to the risk factors seen in general population, people with type 1 diabetes have 
many diabetes related risk factors. Figure 1 presents the categorization of vascular risk 
factors used in the following chapters, having a special emphasis on smoking and 
alcohol consumption and their impact on other risk factors. 
Figure 1. Interaction between smoking and alcohol and other risk factors for vascular 





























2.5 Traditional risk factors for vascular complications and atherosclerosis 
 
2.5.1 Blood pressure 
 
Hypertension is one of the most important risk factors for CVD. Based on a large meta-
analysis, in people aged 40–69 years, each 20 mmHg difference in systolic blood 
pressure (SBP) or 10 mmHg difference in diastolic blood pressure (DBP), above 115/75 
mmHg is associated with a 2-fold increase in the risk of CVD mortality (74). One study 
with 1.25 million people showed that blood pressure is associated with a significantly 
increased risk of all fatal or nonfatal CVD events and that the risk of CHD, heart failure, 
stroke, and peripheral artery disease increased 25–45% per each 20 mmHg increase in 
SBP (75). Globally, high SBP is the leading risk factor, causing 10.4 million deaths and 
218 million disability-adjusted life years yearly (1). In Finland, the prevalence of 
hypertension (blood pressure ≥140/90 mmHg or the use of blood pressure medication) 
is 57.6% in men and 48.3% in women aged 30 or older(37). 
Hypertension is also one of the major risk factors for the development of micro- and 
macrovascular complications in people with type 1 diabetes. The recent results from 
the Pittsburgh Epidemiology of Diabetes Complications (Pittsburgh EDC) study showed 
that hypertension was associated with an over 3-fold increased risk of any CVD and 
major atherosclerotic cardiovascular events (fatal or nonfatal myocardial infarction or 
stroke) during the 25-year follow-up (76). In the Diabetes Control and Complications 
Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) 
study, the effect of blood pressure on the risk of CVD was significant but lower 
compared to the Pittsburgh EDC study results (77). In the DCCT/EDIC study, people with 
high blood pressure at baseline were excluded from the study, which might explain the 
difference between the studies. In the EURODIAB study, SBP was associated with the 
development of CHD but only significantly so in women (78). Based on the recent 
findings of the FinnDiane study, SBP was associated with an increased risk of both 
ischemic and hemorrhagic stroke, but DBP was only associated with an increased risk 
of hemorrhagic stroke (79).  
Several observational studies on type 1 diabetes have shown that elevated blood 
pressure is associated with the development of microalbuminuria and 
macroalbuminuria (80-82). In addition, based on large clinical interventional studies, 
treating patients with microalbuminuria with angiotensin-converting-enzyme inhibitor 
or with an angiotensin II receptor blocker decreases progression to macroalbuminuria 
and increases regression to normoalbuminuria (83). 
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In the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), hypertension 
was strongly associated with the development of incident proliferative diabetic 
retinopathy (84). Other studies have shown an increased risk of diabetic retinopathy or 
its progression in people with higher SBP or DBP (69, 85, 86). Hypertension is also 
associated with the development of both distal symmetrical polyneuropathy and 
cardiac autonomic neuropathy in people with type 1 diabetes (87-89).  
Based on the ADA recommendations, blood pressure targets in people with diabetes 
should be determined individually based on the overall cardiovascular risk profile. For 
people with diabetes and higher CVD risk (>15% in 10 years), the blood pressure target 
would be <130/80 mmHg, but with a lower CVD risk a target of <140/90 mmHg would 




An elevated total cholesterol concentration is a risk factor for atherosclerosis and  
thromboembolic complications, such as myocardial infarction and ischemic stroke (92, 
93). Low-density lipoprotein (LDL) cholesterol is accumulated in the intima layer of the 
arterial wall and causes plaque formation through an inflammatory process (94). High 
LDL cholesterol is particularly associated with a higher risk of CHD, but the association 
with ischemic stroke is still inconsistent (92, 95, 96). However, high-density lipoprotein 
(HDL) cholesterol is inversely associated with both CHD and ischemic stroke (92, 97, 
98). Lowering LDL with statin treatment reduces the mortality and morbidity risk of all 
major vascular events, including a 20–30% reduction in CHD and a 22% reduction in 
ischemic stroke per each mmol/L LDL cholesterol (99, 100).  
In general, the lipoprotein profile in people with type 1 diabetes is less atherogenic 
compared to that in people without diabetes, and the role of triglycerides seems to be 
more important in the development of CVD (101-103). In the DCCT/EDIC study, the 
strongest lipid parameters that predicted CVD were elevated triglycerides and LDL 
cholesterol (77). In the Pittsburgh EDC study, both HDL and non-HDL cholesterol were 
associated with the risk of CHD (104). Gender differences were discovered in the 
EURODIAB study, and HDL cholesterol was inversely associated with the risk of CHD in 
both men and women, but triglycerides were predictive of CHD only in women (78).  
Diabetic nephropathy is associated with elevated total cholesterol, LDL cholesterol, and 
triglycerides and more atherogenic apolipoprotein-based profiles. In people with type 
1 diabetes with normal UAER, instead of LDL cholesterol the ratios of atherogenic and 
28 
 
antiatherogenic lipoproteins and lipids are shown to be the strongest predictors of CHD 
(105). However, in people with macroalbuminuria, total and LDL cholesterol are 
predictive of CHD. Diabetic nephropathy not only alters the lipid profile but several lipid 
abnormalities, particularly elevated triglycerides, which also predict the progression of 
diabetic nephropathy in people with type 1 diabetes (106).  
Based on an older study including participants with type 1 and type 2 diabetes, 
triglycerides are considered a risk factor for proliferative diabetic retinopathy (107). In 
a more recent study on type 1 diabetes, low HDL cholesterol and elevated triglycerides 
were associated with the risk of diabetic retinopathy (108). However, in a larger meta-
analysis, including studies on type 1 and type 2 diabetes, only elevated total cholesterol 
was associated with diabetic macular edema but not with other types of diabetic 
retinopathy. A recent Mendelian randomization study on type 2 diabetes could not 
show any associations between the tested lipid fractions and diabetic retinopathy (69, 
109). Many previous studies concerning the effect of statin therapy on the incidence or 
progression of diabetic retinopathy have had conflicting results (110). However, a 
recent large Taiwanese study showed that people with type 2 diabetes who were using 
statins had a 14% lower risk of incident diabetic retinopathy compared with a group 
not using statins (111). In the Fenofibrate Intervention and Event Lowering in Diabetes 
and Action to Control Cardiovascular Risk in Diabetes studies including patients with 
type 2 diabetes, triglyceride-lowering fenofibrate treatment was associated with a 
lower risk of diabetic retinopathy progression (112, 113).  
Based on the EURODIAB study, elevated triglycerides, total cholesterol, and LDL 
cholesterol were all associated with the progression of diabetic neuropathy (peripheral 
or autonomic) (89). In the previously mentioned Taiwanese diabetic retinopathy study, 
statin treatment was also associated with a 15% lower risk of new-onset diabetic 
neuropathy (111). However, further research is needed to clarify the effect of statin 
treatment on the prevention of different forms of diabetic neuropathy, particularly in 
people with type 1 diabetes.  
Based on the recent guidelines of the European Society of Endocrinology and the 
European Society of Cardiology, statin therapy is recommended for all adults with type 
1 diabetes who have LDL cholesterol over 1.8 mmol/L (<70 mg/dL) and who are 40 or 
over or who have a duration of diabetes longer than 20 years or who have 
microvascular complications (114). In people with a very high risk of CVD, the LDL 
cholesterol target is even lower, namely 50% reduction and less than 1.4 mmol/L (<55 
mg/dL). If the target is not achieved with statins, an additional LDL cholesterol-lowering 
therapy (ezetimibe or proprotein convertase subtilisin/kexin type 9 inhibitor) should be 





Complex inflammatory pathways are involved in all phases of the atherosclerotic 
process—in early atherogenesis, in the progression of lesions, and in thromboembolic 
complications (116). Endothelial and inflammatory cells are activated, and numerous 
different pro-inflammatory cytokines, such as tumor-necrosis factor-α, interleukin-1β 
and interleukin-6 are involved in the process (116). Elevated levels of inflammatory 
markers, such as C-reactive protein (CRP) and fibrinogen, are associated with 
atherosclerosis and an increased risk of CVD (117-119).  
In the Pittsburgh EDC study including 603 people with type 1 diabetes, the white blood 
cell count was associated with an increased risk of CHD (104). Several low-grade 
inflammatory markers and markers of endothelial dysfunction, such as CRP, 
interleukin-6, soluble vascular cell adhesion molecule, soluble E-selectin, plasminogen 
activator inhibitor 1, and fibrinogen are also associated with the development of 
diabetic nephropathy (120, 121). 
Based on the WESDR study, soluble vascular cell adhesion molecule, tumor-necrosis 
factor, and elevated homocysteine levels were associated with more severe diabetic 
retinopathy in the presence of diabetic nephropathy. However, only homocysteine was 
associated with a higher risk of macular edema regardless of the diabetic nephropathy 
status (122). In the DCCT/EDIC study, baseline soluble E-selectin and plasminogen 
activator inhibitor 1 were associated with the development of diabetic retinopathy in 
the absence of other diabetic complications. However, many of the traditional 
inflammatory markers, such as CRP, tumor-necrosis factor receptors, and interleukin-
6, were not associated with the development of diabetic retinopathy (123). 
Hyperglycemia-induced low-grade inflammation and endothelial dysfunction are also 
associated with the development of diabetic neuropathy. The pathogenesis of distal 
symmetrical polyneuropathy is a complex network of biochemical mechanisms, 
including low-grade inflammation, endoplasmic reticulum stress, endothelial 
dysfunction, oxidative stress, and impaired mitochondrial function, all leading to neural 
damage (124).   
Despite the increasing knowledge regarding the inflammatory process in the 
development of vascular complications, so far statins are the only medications used in 
clinical practice that have an anti-inflammatory effect in addition to lowering LDL 
cholesterol (125). However, a number of agents targeting different inflammatory 
pathways are being studied, and in the future some of them might be useful in 
preventing CVD (126). 
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2.5.4 Insulin resistance 
 
Insulin resistance is defined as impaired insulin action in insulin-sensitive target tissues, 
such as skeletal muscle, adipose tissue, and the liver, leading to hyperglycemia, low-
grade inflammation and dyslipidemia. Insulin resistance is an important predictor of 
the development of type 2 diabetes; it accelerates the progression of atherosclerosis 
and is causally associated with CVD events (127). Insulin resistance or sensitivity is 
traditionally measured by the glucose disposal (infusion) rate (GDR) using a euglycemic 
hyperinsulinemic glucose clamp test, or it can be estimated using methods such as the 
homeostasis model assessment or models based on an oral glucose tolerance test (128-
130). In patients with type 1 diabetes,  insulin sensitivity, can also be indirectly 
estimated based on an equation including the waist-to-hip ratio (WHR), history of 
hypertension, and the HbA1c level, yielding an estimated glucose disposal rate (eGDR) 
(131). Lower eGDR values reflect lower insulin sensitivity (i.e., insulin resistance).  
Although insulin resistance is a characteristic feature in people with type 2 diabetes, it 
is also commonly seen in people with type 1 diabetes (132, 133). Based on both the 
Pittsburgh EDC and the DCCT/EDIC studies, low eGDR is associated with an increased 
risk of CHD (104, 134). CVD risk is also elevated in people with type 1 diabetes who 
have a family history of type 2 diabetes, confirming the role of insulin resistance in the 
development of CVD (135). 
Many studies have shown that insulin resistance is a risk factor for the development of 
diabetic nephropathy, and impaired insulin sensitivity is found in people with 
microalbuminuria, which partly explains the increased risk of CVD associated with 
diabetic nephropathy (134, 136-138). Increased insulin resistance also strongly 
correlates with a higher risk of diabetic retinopathy and neuropathy (89, 134, 139, 140). 
The combination of type 1 diabetes and insulin resistance is often called “double 
diabetes”, and some of the medications used in treating type 2 diabetes have also been 
tested in patients with type 1 diabetes with this particular condition. Although 
metformin, glucagon-like peptide-1 receptor agonists and SGLT2 inhibitors have some 
beneficial effects on body weight, lipid profile, HbA1c values, and the insulin 
requirement, so far, the use of these medications has been limited to a selective group 







The prevalence of obesity and overweight has been increasing globally during the last 
decades, causing excess morbidity and mortality. Based on WHO’s Global Health 
Observatory data, 39% of the adult population and 18% of children and adolescents 
were overweight or obese in 2016 (145). Although the increase in adult obesity in 
developed countries has slowed, the prevalence of obesity among children is still 
growing, especially in developing countries (146, 147). Obesity is one of the major 
modifiable risk factors for CVD, and elevated BMI is associated with both fatal and 
nonfatal CHD and stroke (148, 149).  
Obesity is traditionally measured by BMI, calculated as weight in kilograms divided by 
height in meters squared. The definition of obesity is BMI of ≥30.0 kg/m2, while 
overweight is defined as BMI from 25.0–29.9 kg/m2 (150). Regarding all-cause 
mortality, an optimal BMI seems to be 22.5–25.0 kg/m2 and each 5 kg/m2 higher BMI 
is associated with a 30% higher overall and 40% higher vascular mortality (151). 
However, based on the large INTERHEART study, WHR seems to have a stronger 
association with the risk of myocardial infarction compared with BMI, and the top two 
quintiles of WHR increase the population-attributable risk of myocardial infarction by 
24.3% compared with only  a 7.7% increased risk seen with the top two quintiles of BMI 
(152). 
In people with type 1 diabetes, WHR, body weight, and BMI are all shown to be 
associated with the risk of CVD. However, the results have varied between studies, and 
gender differences have been reported. In an earlier report from the EURODIAB study, 
WHR was associated with a higher risk of CHD in men but not in women, and BMI was 
not a significant risk factor in that study (78). However, in a later CVD risk model analysis 
based on EURODIAB and two other cohort studies, WHR was a significant risk factor for 
major CVD outcomes, and each 0.1 unit increase in WHR increased the CVD risk by 30% 
(153). In a recent study from the Pittsburgh EDC, higher body weight and BMI were 
associated with the development of CVD in men but not in women (76). 
In people with insulin-treated diabetes, weight gain and higher BMI are often 
associated with tighter glucose control, and therefore the effect on the risk of CVD 
related to weight gain might be different compared with the general population. In the 
DCCT/EDIC study, excess weight gain and obesity were associated with intensive 
treatment of glycemia. In a later report, excess weight gain was also associated with a 
higher coronary calcium score and intima media thickness, indicating a higher CVD risk 
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(154, 155). Excess weight gain should therefore be limited during intensive glucose 
treatment.  
Obesity is also a risk factor for microvascular complications in people with type 1 
diabetes. Both higher BMI and WHR are associated with the development of diabetic 
nephropathy, and higher BMI is associated with the development of diabetic 
retinopathy and neuropathy (86, 89, 156, 157). Based on the EURODIAB study, both 
body weight and BMI are associated with an increased risk of distal symmetric 
polyneuropathy (89).  
In people with type 2 diabetes, weight loss (especially after bariatric surgery) might 
even lead to remission of diabetes and therefore to a reduced risk of macrovascular 
and microvascular complications (158). Based on a recent study including people with 
type 2 diabetes, bariatric surgery was associated with a significantly lower cumulative 
incidence of all-cause mortality, CHD, stroke, heart failure, atrial fibrillation and 
diabetic kidney disease compared with nonsurgical treatment (159). Studies have also 
shown a reduced risk of incident microvascular disease (diabetic nephropathy, 
retinopathy, and neuropathy) after bariatric surgery (160-162). Studies of bariatric 
surgery that have included people with type 1 diabetes are scarce but have shown 
favorable effects of weight loss on insulin requirement, glycemic control, blood 
pressure and lipid profile (163, 164). A small study including people with type 1 diabetes 
showed a potentially positive effect of bariatric surgery on diabetic nephropathy, while 




Age is the strongest risk factor for any CVD. Globally, the prevalence of CHD is low in 
the younger age groups but starts to increase significantly after the age of 40. The 
prevalence of CHD is 3-fold higher in people aged 50–54 compared to those aged 40–
44 (36). Similarly, the risk of stroke and peripheral artery disease increases with 
increasing age. In Finland, the prevalence of CHD increases from 5.2% in men aged 50–
59 to 28% in men ≥80, and the corresponding percentages in women are 2.2% and 
26.3% (37).       
In studies of people with type 1 diabetes, age at onset of diabetes and diabetes 
duration are the more often used time variables instead of age. However, many studies 
have also reported data regarding the effect of age on the risk of different vascular 
complications. In the DCCT/EDIC study, age was the strongest risk factor for the 
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development of any CVD and major atherosclerotic cardiovascular event, with a linear 
association where every 5 years increased the risk of any CVD by 54% and increased 
the risk of major atherosclerotic cardiovascular event by 77% (77). The results from the 
EURODIAB study were similar, with a 93% increased risk of CVD per decade (153).   
In people with type 1 diabetes, older age is also associated with the progression of 
diabetic nephropathy and a decline in kidney function measured by eGFR (166, 167). In 
the DCCT/EDIC study, age was associated with a higher risk of proliferative diabetic 
retinopathy and the risk increased by 1.4% per 1 year (168). A 10-year increase in age 
is associated with a 50% increase in the risk of incident cardiac autonomic neuropathy, 





2.5.7.1 Sex differences in macrovascular disease     
 
Gender differences are observed in the risk of different cardiovascular outcomes. 
Atherosclerosis is rare in premenopausal women, but due to postmenopausal 
hormonal changes, the suboptimal primary and secondary prevention of CVD risk 
factors, and the longevity of women, the lifetime risk of CVD increases to a higher level 
in women compared to men (35, 169-171).  
While women and men mostly share the same traditional cardiovascular risk factors, 
some differences were observed in the risk factor profile for acute myocardial 
infarction in the INTERHEART study. Hypertension, diabetes, physical activity, and 
moderate alcohol consumption were more strongly associated with myocardial 
infarction in women and former smoking in men. Other risk factors, such as 
dyslipidemia, current smoking, and obesity, had similar effects on the risk of myocardial 
infarction in both men and women (172). A history of pre-eclampsia and gestational 
diabetes are sex-specific risk factors for CVD seen in women. Pre-eclampsia doubles the 
risk of ischemic heart disease, and gestational diabetes increases the risk of any CVD by 
70%, largely due to the increased risk of subsequent type 2 diabetes (173, 174).  
Based on the recent Heart Disease and Stroke Statistics 2019 from the US, the 
prevalence of CHD is higher in men in all age groups compared with women; the total 
prevalence is 7.4% for men and 6.2% for women (35). Women are likely to suffer their 
first CVD event later than men; the average age for the first myocardial infarction is 
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65.6 for men and 72.0 for women. However, mortality after an acute myocardial 
infarction is higher in women compared with men in all age groups over 45 (35). The 
risk of heart failure is similar in men and women, although the cumulative lifetime risk 
is higher in women because of their higher life expectancy (35). Women also have a 
higher lifetime risk of any type of stroke than men, at 20–21% compared to 14–17%. 
The age-specific incidence rate of stroke is lower in women in the younger and middle-
age groups but equal or higher in the oldest age groups (35). Based on the INTERSTROKE 
study, among the key risk factors for stroke, blood pressure and WHR were stronger 
for women and current smoking was stronger for men (4). The most important sex-
specific risk factors for stroke in women are pre-eclampsia with an approximately 3-
fold increased risk, gestational hypertension with a 60% increased risk, and the use of 
oral contraceptives with up to a 2-fold increased risk (175).   
Based on a report published in 2016, the prevalence of self-reported CVD in Europe is 
9.2%, the same for both sexes. However, in Finland the prevalence is higher in men at 
13.0% compared with women at 10.9%. In Europe, the CVD mortality is higher in 
women, accounting for 49% of all deaths in women; this is compared with 40% of all 
deaths in men. Mortality in CHD is similar in both sexes, but women have a higher 
mortality in stroke and other forms of CVD. However, the premature mortality in CVD 
before 65–75 is clearly higher in men (34). 
In the presence of diabetes, the protective effect of estrogen in premenopausal women 
is diminished, and women with type 2 diabetes have a 44% greater relative risk of fatal 
CHD compared with men (176). In type 1 diabetes, the CVD risk in premenopausal 
women is greater compared to women without diabetes, and the overall CVD risk 
seems to be similar compared to the CVD risk for men with type 1 diabetes (40). A 
recent meta-analysis of people with both type 1 and type 2 diabetes showed that 
diabetes is a stronger risk factor for stroke in women, increasing the relative risk by 
27% compared to men (177). Based on the Nurses’ Health Study, both type 1 and type 
2 diabetes were associated with increased risk of stroke. However, the association was 
stronger in women with type 1 diabetes, with a 4-fold higher risk of stroke compared 
to women without diabetes. The risk in women with type 2 diabetes was 2-fold higher 
(46). Based on the Coronary Calcification in Type 1 Diabetes study, gender differences 
in insulin resistance-associated factors, such as WHR, waist circumference, and visceral 
fat distribution, could explain a part of the increased CVD risk seen in women with type 




2.5.7.2 Sex differences in microvascular disease     
 
In people with type 1 diabetes, the risk of initial microalbuminuria and the development 
of macroalbuminuria is higher in men compared with women (82, 179). However, the 
sex difference in the risk of ESRD is modified by the age at onset of diabetes, and the 
risk is similar in men and women when diabetes is diagnosed early in life before age 10, 
but the risk is higher in men if the age at onset is 10 or older (180). Data regarding the 
association between sex and the development of diabetic retinopathy are conflicting. 
The large WESDR showed that men have a 33% higher risk of progression of diabetic 
retinopathy, but in some later studies the risk of diabetic retinopathy was similar in 
men and women (69, 84, 86, 181). Based on the FinnDiane study, also the risk of 
diabetic retinopathy is increased in men compared to women in association with 
increasing age at onset (180). In the EURODIAB study, there were no gender differences 
in the risk of developing distal symmetrical polyneuropathy or cardiac autonomic 
neuropathy in people with type 1 diabetes (88, 89). 
 
2.6 Family history and genetics 
 
A family history of CVD is a known risk factor for cardiovascular events. In the offspring 
cohort of the Framingham Heart Study, premature CVD (before the age of 55 in fathers 
and before the age of 65 in mothers) in at least one parent doubled the CVD risk in the 
offspring (182). Based on the same cohort, sibling CVD events increased the CVD risk 
by 50% (183). Previous studies have also shown familial clustering of diabetic 
nephropathy and proliferative diabetic retinopathy, suggesting a genetic component in 
the pathogenesis of these complications in people with type 1 diabetes (184, 185). For 
example, if one of the siblings in a sibling pair with type 1 diabetes has diabetic 
nephropathy, the risk in the other sibling is doubled (186).  
In recent years, large GWAS and whole genome sequencing studies have found multiple 
gene loci associated with different vascular complications, such as CHD, diabetic 
nephropathy, and retinopathy (187-192). There are also some data regarding the 
association between genes and different types of diabetic neuropathy (193). Most of 
the genetic variants, single nucleotide polymorphisms (SNP), found in these studies are 
common and have only a small effect on the overall risk. However, these SNPs can be 
combined to construct genetic risk scores. In a study of CHD, a genetic risk score of 
nearly 50 000 SNPs improved the CHD risk prediction compared with traditional risk 
scores and demonstrated that a healthier lifestyle may compensate for the genetically 
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increased CHD risk (194). Genetic research can also lead to discoveries of new 
therapeutic agents to prevent vascular complications, such as the LDL cholesterol 
lowering proprotein convertase subtilisin/kexin type 9 antibodies that can decrease the 
LDL cholesterol up to 50–60% and reduce CVD morbidity by 15–25% (195, 196).   
Based on current knowledge, genes alone account only for a small part of the risk of 
vascular complications. Recently, new technologies such as epigenomics, 
transcriptomics, proteomics, and metabolomics have provided new understanding of 
the link between genetic code and final functional consequences (197). Hopefully, in 
the future these data could be used to identify people at the highest risk of 
cardiovascular complications and to develop new therapeutic approaches for the 
treatment of vascular complications in people with diabetes.  
    
2.7 Diabetes-related risk factors for vascular complications 
 
Multiple studies have shown that people with type 1 diabetes have a 2–10-fold 
increased risk of CVD morbidity and mortality (198-200). Despite improvements in the 
treatment of cardiovascular risk factors and glycemia during the last 20 years, CVD 
mortality is still higher in people with type 1 diabetes compared with the general 
population (38, 201, 202). This is largely but not completely explained by the increased 
risk of CVD associated with diabetic nephropathy. However, glycemic control and other 
diabetes-related factors have also an effect on the development of CVD outcomes.  
 
2.7.1 Duration of diabetes and age at onset of diabetes 
 
Based on the DCCT/EDIC study, the risk of any CVD is increased by 25% and the risk of 
major atherosclerotic cardiovascular event by 33% per 5 years of duration of diabetes 
(77). A study based on the Swedish diabetes register, showed that early age at onset of 
type 1 diabetes (0–10 years) is associated with up to 5-fold increased excess CVD risk 
compared with later age at onset (26–30 years) (39).  
In addition, the risk of microvascular complications is increased with the increasing 
duration of diabetes in people with type 1 diabetes. The risk of microalbuminuria is 
increased by 3.3% and the risk of macroalbuminuria is increased by 5.4% per one year 
of duration of diabetes (179). However, early age at onset has a protective effect on 
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the development of diabetic nephropathy, and prepubertal age at onset is associated 
with delayed onset of microalbuminuria (179, 203).    
The prevalence of any diabetic retinopathy is higher with longer duration, being 21.1% 
with a duration <10 years compared to 76.3% with a duration ≥20 years (69). Based on 
the DCCT/EDIC study, an increase in the duration by one year increased the risk of 
different types of diabetic retinopathy; it increased proliferative diabetic retinopathy 
by 11.4%, clinically significant macular edema by 9.1%, and the necessity of ocular 
surgery by 8.9% (168). The association between age at onset and the risk of diabetic 
retinopathy is unclear. In the EURODIAB and FinnDiane studies, prepubertal age at 
onset was associated with a higher risk of incident proliferative diabetic retinopathy 
(204, 205). However, in other studies early prepubertal age at onset was associated 
with a lower risk of diabetic retinopathy (203, 206, 207).   
The risk of developing distal symmetrical polyneuropathy increases with the duration 
of diabetes, and in people with type 1 diabetes who have a duration of ≥15.8 years the 
risk is almost 3 times higher compared with those who have a duration of <15.8 years 
(87). Based on the Pittsburgh EDC study, longer duration of diabetes is also a strong risk 
factor for diabetic autonomic neuropathy (208). The effect of age at onset on the 
development of diabetic neuropathy is seldom studied or separately reported, but in 
the Pittsburgh EDC study people who developed cardiac autonomic neuropathy during 
follow-up were younger at the time of diabetes diagnosis compared with those who 
did not develop neuropathy (7.9 vs. 9.3 years) (209). 
 
2.7.2 Glycemic control 
 
The association between glycemia and CVD risk in people with type 1 diabetes is 
unclear due to conflicting results in different studies. Many previous studies have not 
been able to show an association between glycemic control and the risk of CHD (78, 
104, 210, 211). However, based on the latest data from the DCCT/EDIC study, the initial 
intensive treatment was associated with a 42% reduced risk of any CVD at 20 years of 
follow-up and a 30% reduced risk at 30 years. The risk of major cardiovascular events 
was reduced by 57% at 20 years of follow-up and by 32% at 30 years of follow-up. The 
difference was mainly due to the lower HbA1c values during the study period. However, 
the higher incidence of microalbuminuria and albuminuria in the conventional 
treatment group might explain part of the increased CVD risk (212, 213). In the 
DCCT/EDIC study, a 10% reduction (e.g., 7.2% vs. 8.0%) in HbA1c value during the 6.5-
year study period was associated with a 20% reduction in the CVD risk during the 20 
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years of follow-up. In addition, later data from the EURODIAB and Pittsburgh EDC 
studies support the detrimental effect of poor glycemia on the risk of CVD in people 
with type 1 diabetes (153, 214). 
Poor glycemic control is one of the key risk factors for the development of 
microalbuminuria and overt diabetic nephropathy in people with type 1 diabetes. 
Based on different studies, a 1% change in the HbA1c value increases the risk of 
developing microalbuminuria by 13–18% (166, 179, 215). In the original Diabetes 
Control and Complications Trial (DCCT), intensive insulin therapy with close to normal 
glucose values (mean HbA1c value around 7%) compared with conventional therapy 
(mean HbA1c value around 9%) was associated with a 39% reduction in 
microalbuminuria and a 54% reduction in macroalbuminuria after 6.5 years of follow-
up (216). Intensive insulin treatment has a long-term favorable effect on the 
development of diabetic nephropathy, and the difference between the two original 
DCCT treatment groups was still evident after 18 years of follow-up with a 51% 
reduction in the risk of ESRD in the intensive treatment group compared with 
conventional therapy (217, 218).    
Glycemia is also one of the strongest risk factors for diabetic retinopathy. Based on the 
original results from the DCCT, after 6.5 years of follow-up intensive treatment of 
glycemia resulted in a 76% reduction of the risk of any incident diabetic retinopathy 
and a 54% reduction in the risk of three or more step progression of diabetic 
retinopathy. In addition, the risk of proliferative or severe nonproliferative diabetic 
retinopathy was reduced by 47% (216). This beneficial effect of intensive treatment 
was still observed 18 years after the original DCCT trial ended, with a 46% reduction in 
the risk of diabetic retinopathy progression in the former intensive treatment group 
compared with the former conventional treatment group, indicating a strong effect of 
metabolic memory on the development of diabetic retinopathy (85).  
Based on the EURODIAB study, a 1% increase in HbA1c is associated with a 36–44% 
increased risk of any diabetic neuropathy (89). In the DCCT study, combined peripheral 
sensorimotor and autonomic neuropathy was reduced by 60% in the intensive 
treatment group (216). The beneficial effect persisted, and the risk of incident 
peripheral neuropathy was 30% lower and the risk of cardiac autonomic neuropathy 
was 31% lower in the original intensive treatment group after the extended 14-year 
follow-up of the DCCT/EDIC (71). Most forms of diabetic neuropathy lack specific 
treatment, and therefore achieving good glycemic control is crucial in preventing 




2.7.3 Microvascular complications and risk of other vascular complications 
 
2.7.3.1 Diabetic nephropathy 
 
Based on the DCCT/EDIC study, compared with people with type 1 diabetes who have 
normal UAER, microalbuminuria is associated with a nearly 2-fold increased risk of any 
CVD and macroalbuminuria is associated with a 2–3-fold increased risk (77). In the 
FinnDiane study, people with type 1 diabetes were compared with a control group 
without diabetes. The results showed that microalbuminuria was associated with a 6-
fold increased risk of CHD, macroalbuminuria was associated with a 13-fold increased 
risk and ESRD was associated with an up to 27-fold increased risk (40). Similarly, the 
risk of stroke increased with the progression of diabetic kidney disease. Based on the 
DCCT/EDIC data, the risk of CVD seems to remain high even if once sustained 
microalbuminuria returns to normal UAER (219). 
 
Diabetic nephropathy is also a risk factor for the development of diabetic retinopathy 
and neuropathy. Based on the DCCT/EDIC and WESDR studies, the risk of proliferative 
diabetic retinopathy is 2–2.5-fold higher in people with type 1 diabetes who have 
micro- or macroalbuminuria compared with normal UAER. Based on the EURODIAB 
study, UAER is also an independent risk factor for neuropathy, and when exceeding the 
level of macroalbuminuria the risk of any neuropathy is doubled (89). 
 
2.7.3.2 Diabetic retinopathy and neuropathy 
  
Diabetic retinopathy is associated with an increased risk of CVD. WESDR showed that 
the severity of diabetic retinopathy is associated with the risk of CHD (angina but not 
myocardial infarction), stroke, and cardiovascular mortality (210). In the EURODIAB 
study, both nonproliferative and proliferative diabetic retinopathy were associated 
with an increased risk of CVD, although the association was not independent but largely 
explained by traditional CVD risk factors (220). Based on a recent report from the 
FinnDiane study, severe diabetic retinopathy is associated with a nearly 50% increased 
risk of any CVD or CHD and a 90% increased risk of peripheral artery disease (221). 
Diabetic retinopathy is a strong risk factor for the development of other microvascular 
complications, and any diabetic retinopathy nearly doubles the risk of diabetic 
nephropathy (166). Any diabetic retinopathy also increases the risk of cardiac 
autonomic neuropathy by 70%, and proliferative diabetic retinopathy doubles the risk 
(88, 209). Cardiac autonomic neuropathy is associated with higher overall mortality and 
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an increased risk of several cardiovascular complications, such as left ventricular 
dysfunction, silent myocardial ischemia, mortality after myocardial infarction, and 
possibly even stroke (222-224). Diabetic neuropathy is also associated with an 
increased risk of diabetic nephropathy and retinopathy (215, 225). 
 
2.8 Smoking and risk of vascular complications 
 
Cigarette smoke is a mixture of more than 4000 different chemicals many of which are 
involved in the pathogenesis of atherosclerosis. Carbon monoxide and nicotine have 
acute effects on the vasculature through hypoxemia and vasoconstriction caused by 
activation of the sympathetic nervous system. Nicotine is also the main substance in 
cigarette smoke that causes dependency. However, other compounds such as different 
oxidants, play a more crucial role in the formation of atherogenic plaque, through 
endothelial dysfunction and injury, increased inflammation, and platelet activation 
(226). 
 
2.8.1 Effect of smoking on vascular risk factors 
 
2.8.1.1 Blood pressure 
 
Based on experimental studies, smoking causes an acute increase in arterial wall 
stiffness and blood pressure that is mediated through catecholamine release caused by 
nicotine (227, 228). However, the long-term effect of smoking on the blood pressure is 
less clear. A large English population-based study found higher SBP only in older men 
who were heavy or moderate smokers compared with non-smokers (229). In contrast, 
in women there was a trend of lower blood pressure in light smokers. The association 
between smoking and blood pressure is also strongly affected by BMI and alcohol 
intake; therefore, the independent effect of smoking on blood pressure seems to be 
small. Experimental data of people with type 1 diabetes showed a higher 24-h 
ambulatory blood pressure in current smokers compared with non-smokers, possibly 






Smoking has detrimental effects on the serum lipid and lipoprotein concentrations. A 
comprehensive meta-analysis from 1989 showed that current smokers have higher 
serum concentrations of total cholesterol, triglycerides, very low-density lipoprotein 
and LDL cholesterol, and lower concentrations of HDL cholesterol and apolipoprotein 
A1 compared with non-smokers (231). The same meta-analysis showed a dose-
response relationship between smoking and lipid metabolism, and a more atherogenic 
lipid profile is seen in heavy smokers compared with never smokers or light smokers 
(231). Smoking affects the lipid metabolism through different pathways, such as an 
increased catecholamine release that leads to increased free fatty acid concentration 
and increased very low-density lipoprotein formation (232). The triglyceride 
metabolism is affected by smoking through reduced lipoprotein lipase activity in 
skeletal muscle, leading to increased triglyceride levels. The altered triglyceride 
metabolism also affects the size of the LDL cholesterol particles leading to a lower and 
more atherogenic ratio of large to small LDL cholesterol particles. Smoking also induces 
oxidative stress, leading to lipid peroxidation and atherogenic plaque formation. HDL 
cholesterol, and particularly HDL2 cholesterol, is reduced due to smoking through 
decreased lecithin cholesterol acyl-transferase activity and possibly also through 
increased cholesterol ester transfer protein and hepatic lipase activity. These altered 
metabolic mechanisms lead to dysfunctional HDL cholesterol and impaired reverse 
cholesterol transport into the liver (233).  
In people with diabetes, the atherogenic effect of smoking on lipid values is similar to 
that in general population. Based on a meta-analysis of six studies combining people 
with type 1 and type 2 diabetes, non-smokers have lower LDL cholesterol and higher 
HDL cholesterol levels compared with current smokers (234). 
 
2.8.1.3 Inflammation and hemostatic factors 
 
Smoking is associated with increased inflammatory activation, measured by higher 
levels of CRP, white blood cells, interleukin-6, and fibrinogen in current smokers 
compared with never smokers (235, 236). In addition, people with type 1 diabetes who 
were active smokers had a higher leucocyte count compared with never smokers, 
indicating increased inflammatory activity (237). Smoking affects several stages of the 
coagulation and fibrinolytic pathways through increased levels of tissue factor, 
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thrombin, fibrinogen, and plasminogen activator inhibitor 1, leading to an increased 
risk of thromboembolic complications (226, 235).  
 
2.8.1.4 Glucose metabolism and insulin resistance 
 
In healthy people, smoking acutely impairs insulin action, probably due to a lower 
peripheral glucose uptake, leading to insulin resistance (238, 239). In people with type 
1 diabetes, smoking is associated with poorer glycemic control, measured by higher 
HbA1c levels in current smokers (240-244). Smoking is also associated with a higher daily 
insulin requirement, a sign of insulin resistance (245). Some studies have shown that 
smoking is associated with a lower risk of type 1 diabetes (246, 247). 
The risk of type 2 diabetes is increased in a dose-response manner among smokers, 
probably due to the unfavorable effects on glucose metabolism (248-252). In a large 
meta-analysis including people with type 2 diabetes, HbA1c levels were higher in both 
current and former smokers (253). However, there was no difference in fasting plasma 
glucose in current smokers compared with never smokers, and in fact the 2-h plasma 
glucose was lower in the current smokers. Therefore, the diagnosis of type 2 diabetes 
in current smokers might depend on the specific glycemic variable used as a diagnostic 
criterion. The prevalence of type 2 diabetes among smokers is higher if an elevated 
HbA1c level is used for the diagnosis instead of the 2-h plasma glucose. 
 
2.8.1.5 Obesity  
 
Compared with non-smoking, current smoking is associated with lower body weight, 
lower BMI, and lower weight gain after the age of 25, in both men and women (254). 
However, there is some evidence that smoking is associated with increased abdominal 
fat and WHR; therefore, the overall cardiometabolic effect would be negative despite 







2.8.2 Gene-smoking interaction and DNA methylation 
 
Candidate gene studies have conducted gene-smoking interaction analyses with 
previously known candidate gene loci for CHD. Seleheen et al. analyzed gene–smoking 
interaction at 50 loci associated with CHD risk and found that the 12% cardioprotective 
effect of the ADAMTS7 locus seen in never smokers was halved in current smokers 
(256). In another smaller study, a CHD risk allele was associated with an increased risk 
of CHD and CVD mortality only in never smokers, and the risk was attenuated in 
smokers (257). These results might be explained by the overall higher CVD risk in 
smokers, but direct changes in molecular and gene levels are also possible.  
Another approach to evaluate gene–smoking interaction is to perform a genome-wide 
smoking–SNP interaction study. These GWAS have found novel loci for several CVD 
markers or risk factors, such as carotid intima-media thickness, coronary artery 
calcification, lipid variables, and blood pressure (258-261). A recent study addressed 
the interaction between a polygenic risk score for CHD and smoking (262). Based on 
the results, never smokers with the highest polygenic risk score had a similar risk of 
CHD compared to current smokers with the lowest polygenic risk score. 
Epigenetic changes in deoxyribonucleic acid (DNA) methylation are one potential 
mechanism behind smoking exposure and different adverse health outcomes. 
Epigenetic studies have found approximately 2600 differentially methylated cytosine-
phosphate-guanine sites (CpGs) in 1400 genes in current smokers compared with never 
smokers. These CpGs are also enriched in smoking-related diseases, such as CVD (263, 
264). Smoking cessation leads to the normalization of methylation levels in most CpGs 
within 5 years of smoking cessation. However, nearly 200 CpGs remain differently 
methylated in former smokers compared with never smokers 30 years after smoking 
cessation, possibly explaining some of the permanent harm of smoking. Differences in 
gene methylation have also been used to design a methylation marker set that can 
identify smoking status, both current and former, from DNA samples (265). This 








2.8.3 Smoking and mortality 
 
The overall mortality is 3 times higher in smokers aged 25–79, compared with never 
smokers, and smoking is associated with a 10-year shorter life expectancy (266). Lung 
cancer mortality is around 15 times higher, and CVD mortality 2–3 times higher in 
smokers compared with never smokers (266). Based on a recent meta-analysis of 
people with diabetes, total and CVD mortality is 1.5 times higher in current smokers 
compared with never smokers (267). The risk seems lower than in the general 
population, but the difference is explained by the higher CVD mortality risk seen in all 
people with diabetes. Based on the same meta-analysis, in people with type 1 diabetes 
the total mortality risk is 1.8 times higher and CVD mortality 1.9 times higher in smokers 
compared with never smokers. 
 
2.8.4 Smoking and cardiovascular disease 
 
Cigarette smoking is one of the major risk factors for CHD. Based on the large 
INTERHEART study, current smoking was associated with a nearly 3 times higher risk of 
acute non-fatal myocardial infarction compared with never smoking, and the risk 
increases linearly with the increasing number of cigarettes smoked per day (2). In the 
INTERHEART study, the increased CHD risk associated with smoking was similar in men 
and women. However, in a large meta-analysis the risk of CHD associated with smoking 
was 25% higher in women compared with men (268). Smoking is also a strong risk factor 
for heart failure and current smokers carry a 2-fold increased risk of heart failure 
compared with never smokers (3, 269).  
Based on the INTERSTROKE study, smoking is one of the five major risk factors that 
account for 80% of the global risk of all stroke, and in current smokers the risk of stroke 
(ischemic or hemorrhagic) is doubled compared with never smokers (4). In addition, 
the risk of stroke is increased with the number of cigarettes smoked per day, and 
people who smoke more than one pack (20 cigarettes) per day have over a 4-fold 
increased risk of stroke compared with never smokers (4). Regarding the risk of stroke, 
smoking is at least equally harmful for women as men, although there is some evidence 
of more harmful effects in women living in Western countries (270). In studies 
regarding both ischemic and hemorrhagic stroke, the majority of events are ischemic. 
However, separate studies regarding only hemorrhagic stroke events have shown an 
increased risk of total hemorrhagic stroke, intracerebral haemorrhage, and 
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subarachnoid hemorrhage in current smokers compared with never smokers (271, 
272).  
In people with diabetes (type 1 and type 2 combined), current smoking is associated 
with approximately 50% higher risk of CHD and stroke compared with never smoking 
(267). Among people with type 1 diabetes, the associations between smoking and 
different CVD disease entities have been studied to a lesser extent, and specific dose-
response data are lacking. In addition, many studies have only addressed CVD mortality 
or combined CVD and not specific CVD events, and the results have been conflicting 
(273, 274). Few studies have shown an increased CHD risk in ever smokers compared 
with never smokers (104, 275). But only in one study was the risk of non-fatal CHD 
higher in former smokers (210). Other studies, including the EURODIAB study, have not 
been able to show significant associations between smoking and the risk of CHD (78, 
274).  
Only two studies have reported findings regarding the association between smoking 
and heart failure in people with type 1 diabetes. A larger study based on the Swedish 
national diabetes registry showed that smoking was associated with an increased risk 
of heart failure but only when a person was registered as a smoker in more than 50% 
of the registration events (276). In a smaller Polish study, smoking was not associated 
with an increased risk of heart failure diagnosed by echocardiography of each study 
subject (277).  
In the general population, smoking is strongly associated with peripheral arterial 
disease, and the risk of intermittent claudication is nearly 4-fold higher in heavy 
smokers (>25 pack-years) compared with never smokers (278-280). In people with type 
1 diabetes, smoking is associated with a 2-fold risk of ulcers and heavier smoking is also 
associated with the risk of lower extremity amputations, with a 30% increased risk per 
10 pack-years of smoking (281, 282). 
 
2.8.5 Smoking and microvascular complications 
  
2.8.5.1 Diabetic nephropathy 
 
In the general population, current smoking is associated with a 2–4-fold increased risk 
of ESRD or death due to chronic kidney disease compared with non-smokers (283, 284). 
The nephrotoxic effect of cigarette smoke is mediated through many different 
mechanisms, such as hypoxia, oxidative stress, prothrombotic factors, pro-
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inflammatory cytokines, intrarenal vasoconstriction, and nicotine-induced cell 
proliferation (285). These mechanisms lead to tubular damage and glomerular sclerosis 
and eventually to a decline in kidney function. 
In addition, in people with diabetes smoking is associated with a decline in kidney 
function measured by eGFR (286). However, results from studies regarding the 
association between smoking and the progression of diabetic nephropathy have been 
conflicting. Older studies with a cross-sectional design or only a short follow-up showed 
that smoking was associated with proteinuria in people with type 1 diabetes (241, 287-
291). In a Danish study with 10 years of follow-up, current smoking was associated with 
a higher risk of developing micro- and macroalbuminuria (166). However, most of the 
later prospective studies with longer follow-up have not confirmed the association 
between smoking and the progression of diabetic nephropathy (82, 215, 244, 286, 292). 
These studies also lack data regarding cumulative smoking in pack-years and intensity 
of smoking in packs per day; therefore, the results are limited to simple smoking status.      
      
2.8.5.2 Diabetic retinopathy and neuropathy 
 
The results regarding the effect of smoking on the risk of diabetic retinopathy or 
neuropathy have varied during different time periods. An earlier cross-sectional study 
from the 1980s reported a positive association between current smoking and the 
prevalence of proliferative diabetic retinopathy in people with type 1 diabetes (287). 
An earlier cross-sectional report from the EURODIAB study showed an association 
between current and ex-smoking and diabetic retinopathy in men (241). However, after 
7.3 years follow-up, current smoking was not associated with the incidence of 
proliferative diabetic retinopathy in the EURODIAB study (204). The results from the 
DCCT/EDIC study were similar to the prospective EURODIAB results, and smoking was 
not associated with the development of proliferative diabetic retinopathy after more 
than 30 years of follow-up (168). In an early report from the Pittsburgh EDC study, ever 
smoking was associated with an increased risk of diabetic autonomic neuropathy, but 
the finding was not confirmed in the later report from the same study or in the 
EURODIAB study (88, 208, 209). However, ever smoking is shown to increase the risk of 





2.8.6 Smoking cessation 
 
While active smoking is associated with the deterioration of many cardiometabolic risk 
factors, some but not all are improved after smoking cessation. Smoking cessation is 
often associated with weight gain that occurs rapidly during the first months after 
smoking is stopped. The mean body weight increase at one year after smoking 
cessation is 4–5 kg, but the inter-individual variation is wide (293). Even though >5 kg 
weight gain after smoking cessation is associated with a higher risk of type 2 diabetes, 
the risk of all-cause and CVD mortality is still reduced in all former smokers compared 
with current smokers (294). Based on experimental studies, smoking cessation can 
within a few weeks acutely improve insulin sensitivity. However, after a few months 
insulin sensitivity deteriorates, probably due to weight gain (295, 296). In people with 
type 2 diabetes, HbA1c is increased during the first 1–2 years after smoking cessation, 
but after that glycemic control improves and by 3 years the HbA1c level is similar to that 
of continual smokers (297). Similar studies of people with type 1 diabetes investigating 
the effect of smoking cessation on glycemic control compared to continual smoking do 
not exist. However, in the EURODIAB study, the HbA1c level was similar in never smokers 
compared with former smokers and higher in current smokers (241). Smoking is 
associated with a more atherogenic lipid profile, which is improved after smoking 
cessation. Despite weight gain, HDL cholesterol is significantly increased after smoking 
cessation, but total cholesterol, LDL cholesterol, and triglycerides are not affected (298, 
299). There is also evidence that the inflammatory process related to smoking is 
attenuated by smoking cessation (300, 301). 
In the general population, smoking cessation has a clear beneficial effect on all-cause 
mortality (266). If smoking is stopped at the age of 25–34, the mortality risk is similar 
to that in never smokers. However, smoking cessation later in life is also beneficial, and 
if smoking is stopped at the age of 55–64, 4 years of life are gained compared with 
people who have continued to smoke. In addition, the risk of CHD is decreased after 
smoking cessation, but based on the INTERHEART study the risk of acute myocardial 
infarction is still 22% higher more than 20 years after quitting in former smokers 
compared with never smokers (2). In former smokers who have stopped smoking >15 
years earlier and who smoked less than 32 pack-years, the risk of heart failure is similar 
compared with never smokers (302). In the INTERSTROKE study, the risk of stroke in 
former smokers decreased even below the risk seen in never smokers (4). However, 
based on a large meta-analysis, the risk of any stroke in former smokers is 17% higher 
in women and 8% higher in men compared with never smokers, and the risk is lower 
compared with current smokers in both men and women (270). The risk of peripheral 
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artery disease is not decreased after smoking cessation to the same degree as the other 
CVD outcomes, and the risk of peripheral artery disease is still 2-fold higher in former 
smokers compared with never smokers (49).  
Some of the older studies have reported a favorable effect of smoking cessation on 
UAER values in people with type 1 diabetes (288, 289). However, the EURODIAB study 
showed contrary results, and the prevalence of macroalbuminuria was the highest in 
men who were former smokers (241). Studies regarding the effect of smoking on the 
risk of diabetic nephropathy have often combined former smokers with never or 
current smokers, and therefore the effect of smoking cessation on development  of 
diabetic nephropathy remains largely unclear (166, 215, 244). As the results regarding 
the association between smoking and the risk of diabetic retinopathy and neuropathy 
are conflicting, there is no clear evidence regarding the effect of smoking cessation on 
the development of these complications either.  
 
2.8.7 Dose-dependent measures of smoking 
 
Traditionally, the dose-dependent analyses regarding smoking and CVD risk have 
included pack-year data. However, the cumulative dose can also be calculated by 
converting the duration of smoking and the intensity of smoking (packs per day) into 
pack-years. A recent epidemiological study compared the effect of the cumulative dose 
of pack-years with the intensity of smoking measured in packs per day on the risk of 
CVD (303). Based on the findings, it seems that the intensity of smoking might be a 
better measure of smoking-related CVD risk compared to pack-years or plain smoking 
status. Both the INTERHEART and INTERSTROKE studies showed a linear association 
between the intensity of smoking (cigarettes per day) and the risk of CHD and ischemic 
stroke (2, 4). Previous studies regarding the risk of CVD in people with type 1 diabetes 
do not provide more accurate data on the effect of cumulative smoking and intensity 
of smoking. 
 
2.8.8 Second-hand smoke 
 
Exposure to second-hand smoke or passive smoking is associated with a 25% increased 
risk of CHD and stroke (304, 305). During the last decades, several actions have been 
taken regarding Finnish tobacco legislation to reduce the harmful effects of second-
hand smoke. The act for smoke-free workplaces was introduced in 1994, and smoking 
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in restaurants was banned in 2007. The prevalence of people exposed to second-hand 
smoke at their work-place has declined from 24% in 1994 to 4% in 2014, when the data 
regarding second-hand smoke were last collected in Finland (306). 
 
2.9 Alcohol and risk of vascular complications 
 
Unlike the harmful effect of smoking across the different disease entities, the effect of 
alcohol consumption is more complex. The detrimental effect of alcohol consumption 
leading to the increased risk of many different forms of cancer, liver cirrhosis, and 
injuries is well established. However, based on numerous epidemiological studies, light-
to-moderate alcohol consumption is associated with beneficial effects on 
atherosclerotic vascular diseases, particularly CHD. Like smoking, alcohol consumption 
affects vasculature through many known cardiovascular risk factors and atherogenic 
pathways.  
 
2.9.1 Effect of alcohol consumption on cardiovascular risk factors 
 
2.9.1.1 Blood pressure 
 
Alcohol consumption is associated with increased blood pressure and experimental 
studies have shown a rapid decrease in the blood pressure after the cessation of alcohol 
consumption (307). A large meta-analysis of clinical trials studying the effect of reduced 
alcohol consumption on blood pressure reported a -3.31 mmHg reduction in the SBP 
and a -2.04 mmHg reduction in the DBP when the mean baseline alcohol consumption 
was 3–6 drinks per day and the average reduction of daily consumption -67% (308). In 
a study of people with hypertension and alcohol dependency the effect of alcohol 
abstinence was even stronger; after a 16-week treatment period SBP decreased 12 
mmHg and DBP decreased 8 mmHg (309). Alcohol consumption beyond two drinks per 
day is associated with an increased incidence of hypertension in both men and women 
(310). The most recent American Heart Association guideline for high blood pressure 
recommends alcohol consumption ≤2 drinks per day for men and ≤1 drink per day for 






Alcohol consumption has well-known effects on lipids. Based on a meta-analysis of the 
effect of alcohol consumption on lipids and hemostatic factors, the largest dose-
dependent effect was on HDL concentration. With an average alcohol consumption of 
30 g (2.5 drinks) per day, HDL cholesterol was 3.99 mg/dl (0.10 mmol/l) higher 
compared with abstainers (312). A smaller increase was also reported for the 
concentrations of triglycerides and apolipoprotein A1. A more recent meta-analysis of 
the effect of moderate alcohol consumption on lipids reported a significant increase 
only in HDL cholesterol (0.09 mmol/l); there was no effect on total cholesterol, LDL 
cholesterol, or triglycerides (313). However, higher alcohol intake per drinking session 
(≥5 drinks) has been shown to elevate triglyceride concentrations (≥150 mg/dl or 1.7 
mmol/l) in both men and women (314).  
 
2.9.1.3 Inflammation and hemostatic factors 
 
Some studies have reported a lower CRP in moderate alcohol consumers compared 
with abstainers and heavy consumers (315, 316). However, this possible anti-
inflammatory effect of moderate alcohol consumption was not fully confirmed in a 
meta-analysis where no significant associations between alcohol consumption and 
CRP, interleukin-6, or tumor-necrosis factor α were found (313). Smaller studies have 
also shown associations between alcohol consumption and different hemostatic 
markers, such as fibrinogen, D-dimer, and plasminogen activator inhibitor 1 (316, 317). 
The strongest effect is on fibrinogen, with a reduction of -0.20 g/l in moderate 
consumers (313).   
 
2.9.1.4 Glucose metabolism and insulin sensitivity 
 
Moderate alcohol consumption is associated with an increase in adiponectin, which 
could lead to improved insulin sensitivity through the suppression of glucose 
production in the liver and increased glucose uptake and fatty acid oxidation in the 
muscles (313, 318). Based on a meta-analysis of intervention studies, moderate alcohol 
consumption decreased fasting insulin and HbA1c, but no significant effect was seen on 
the fasting glucose concentration or insulin sensitivity, except a trend toward increased 
insulin sensitivity in women (319). Moderate alcohol consumption is associated with a 
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lower risk of type 2 diabetes, but based on the latest evidence this association is only 
seen in women, with a peak risk reduction of 18% with an alcohol consumption of 1 
drink per day (320).  
In people with type 1 diabetes, alcohol is associated with an increased risk of 
hypoglycemia, and the decrease in glucose is seen 8–12 hours after alcohol intake. 
Alcohol consumption may also impair cognitive function and therefore blunt 
hypoglycemia awareness. At the molecular level, alcohol suppresses growth hormone 
levels leading, to impaired gluconeogenesis and hypoglycemia (321). 
 
2.9.2 Alcohol consumption and cardiovascular disease 
 
Alcohol consumption influences the development of CVD through complex pathways, 
including the modification of the above-mentioned traditional risk factors and a variety 
of interactions at the cellular and molecular levels (322). Based on multiple 
observational and interventional studies, moderate alcohol consumption seems to 
have a protective effect on some CVD entities. In a large meta-analysis, alcohol 
consumers had 25% reduced CHD mortality and a 27% reduced risk of incident CHD 
compared with life-long abstainers (323). The risk of CHD morbidity and mortality is 
lowest with a consumption of 2–3 drinks per day in men and 1 drink per day in women 
(324). In men, the CHD mortality risk increases with an increasing amount of alcoholic 
drinks, but the CHD morbidity risk seems to remain similar, even with higher 
consumption. However, in women not only the CHD mortality risk but also the 
morbidity risk increases with increasing alcohol consumption and in a steeper manner 
than in men. In former drinkers, the risk of CHD morbidity is similar to that in life-long 
abstainers, but CHD mortality is significantly higher (323, 325). 
Regarding the risk of stroke, the protective effect of alcohol is clearly smaller and only 
seen for the risk of ischemic stroke and not for intracerebral hemorrhage or 
subarachnoid hemorrhage (326). Alcohol consumption of ≤2 drinks per day is 
associated with an 8–10% lower risk of ischemic stroke compared with abstainers, but 
the risk is significantly higher when alcohol consumption exceeds the limit of 2 drinks 
per day. Moderate alcohol consumption has no significant effect on the risk of 
hemorrhagic stroke. However, the risk of hemorrhagic stroke is increased with 
increased alcohol consumption, and heavy drinking (>4 drinks per day) is associated 
with a 67% higher risk of intracerebral hemorrhage and an 82% higher risk of 
subarachnoid hemorrhage (326).  
52 
 
There are no data regarding alcohol consumption and CVD risk in people with type 1 
diabetes, but a few studies of people with type 2 diabetes have shown an association 
between alcohol consumption and a lower risk of CHD. Based on a small meta-analysis 
of six studies, alcohol consumption reduced the risk of total and fatal CHD by 25–66% 
(327). In women with type 2 diabetes, light-to-moderate alcohol consumption is 
associated with a 50% reduction in the risk of fatal or nonfatal CHD (328). In men, the 
results are similar, and regular alcohol consumption or the consumption of >2 drinks 
per day are associated with a lower CHD risk compared with abstainers (329, 330). The 
Action in Diabetes and Vascular Disease (ADVANCE) trial reported that moderate 
alcohol consumption was associated with a 17% lower combined CVD risk, including 
stroke, but no specific data regarding the association between alcohol consumption 
and stroke in people with type 2 diabetes are available (331).   
  
2.9.3 Alcohol consumption and microvascular complications 
 
Only a few previous studies have addressed the association between alcohol 
consumption and microvascular complications in people with diabetes. Based on the 
EURODIAB study, compared with abstainers, moderate alcohol consumers had a lower 
risk of macroalbuminuria, proliferative diabetic retinopathy, and neuropathy (332). 
However, some diabetic retinopathy studies have shown contradictory findings, with 
an increased risk of diabetic retinopathy in either light or heavy consumers (107, 333). 
An early cross-sectional report from the WESDR showed a possible beneficial effect on 
the risk of diabetic retinopathy in people with type 1 diabetes, but their later 
prospective study did not support these earlier findings (334, 335). In the ADVANCE 
trial including people with type 2 diabetes, alcohol consumption was associated with a 
15% reduction in the risk of microvascular complications (diabetic nephropathy or 
retinopathy combined) (331). Based on recent data from the DCCT/EDIC study, 
occasional or regular drinking was not associated with the risk of incident proliferative 
diabetic retinopathy (168). Due to the conflicting results of the different diabetic 
retinopathy studies and the rather scarce data with respect to diabetic nephropathy, 
the overall effect of alcohol consumption on the risk of diabetic retinopathy and 





2.9.4 Effect of drinking pattern and beverage type 
 
Even if light-to-moderate alcohol consumption might have a beneficial effect on some 
CVD outcomes, the effect is strongly influenced by the drinking pattern. Irregular heavy 
drinking occasions, >60 g or ≥5 drinks per occasion at least monthly, are associated with 
up to a 45% increased risk of CHD compared with regular moderate drinking (336). 
Based on a Finnish study, binge drinking increases the risk of any stroke by 85%, and 
the risk of ischemic stroke is nearly doubled compared to non-binge drinkers (337). 
Based on an older review study that collected data from 10 large prospective cohort 
studies, there was no consistent pattern indicating that any specific beverage type 
(wine, beer, or spirits) would have a more beneficial effect on the risk of CHD (338). 
However, later meta-analyses of the effect of wine, beer, and spirit consumption on 
the risk of CVD have reported a protective effect associated with both moderate wine 
and beer consumption, but no significant protective effect was associated with spirit 
consumption (339, 340). In the EURODIAB study, moderate wine consumption was 
associated with a lower risk of both diabetic nephropathy and retinopathy (332). It also 
reported a lower diabetic retinopathy risk in moderate beer consumers but did not find 
any association between spirit consumption and the risk of microvascular 
complications. Based on the ADVANCE trial, in people with type 2 diabetes different 
beverage types were not associated with the risk of diabetic retinopathy (341). 
 
2.9.5 Relationship of alcohol consumption with other environmental risk 
factors 
 
Moderate alcohol consumption and physical activity are both shown to be associated 
with an overall healthier lifestyle (342). There are also differences in environmental risk 
factors between drinkers of different beverage types. Wine drinkers seem to have 
higher socioeconomic status, measured by education and income (343). A Danish study 
showed that people who buy wine also have healthier food-buying habits compared 
with people who buy beer (344). In another Danish study, wine drinking was associated 
with better psychological functioning and higher IQ scores compared with beer drinkers 
(345). A Finnish study reported similar findings, with better self-reported health, higher 
self-efficacy, and less psychological distress in people who regularly drink wine with 
meals (346). Therefore, these many behavioral and socioeconomical characteristics 
that correlate with the choice of drink might largely explain the differences seen in the 
association between beverage type and CVD risk (347). 
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3 AIMS OF THE STUDY 
 
The specific aims of this thesis were as follows: 
I To examine the cross-sectional association between the amount of 
alcohol consumption and the type of beverage and the risk of diabetic 
nephropathy and severe diabetic retinopathy in people with type 1 
diabetes. 
II To evaluate the effect of cumulative smoking in pack-years on the 
development of diabetic nephropathy in people with type 1 diabetes. 
III To evaluate the combined effect of smoking and the rs4972593 gene 
variant on the development of end-stage renal disease in people with 
type 1 diabetes. 
IV To investigate the association between cumulative smoking in pack-
years and the intensity of smoking in packs per day and the risk of 
coronary heart disease, heart failure and stroke in people with type 1 














4 SUBJECTS AND STUDY DESIGN 
 
These studies are part of the ongoing FinnDiane study, a nationwide, multicenter, 
prospective study with the aim of identifying the clinical, genetic, and environmental 
risk factors for micro- and macrovascular complications in people with type 1 diabetes. 
The FinnDiane study was officially launched in 1997, although some participants were 
recruited during the two pilot studies (GENREL and NEFREL) during 1994–1996. The 
participants were recruited at their regular visits to the outpatient clinics at each study 
center (all 5 Finnish university hospitals, 16 central hospitals, 26 regional hospitals, and 
30 primary health care units). Although the FinnDiane study is not strictly population-
based, the distribution of the participants is similar to the distribution of the general 
population in Finland. The recruitment criteria for type 1 diabetes were age <40 when 
the diagnosis was made and initiation of insulin treatment within one year of the 
diagnosis.  
Currently, 5500 people with type 1 diabetes have been recruited to the FinnDiane 
study. A prospective phase of the study was started in 2004 covering approximately 
1900 participants. Follow-up data were also obtained from medical files and regular 
updates of national registers, such as the Care Register for Health Care and the Causes 
of Death Register. All participants have given their informed written consent. The local 
ethics committees have approved the study protocol, and the study is carried out in 
accordance with the principles of the Declaration of Helsinki. 
      
4.1 Study I 
 
The study design of the first study is cross-sectional. This study comprises 4187 
participants who had enrolled in the FinnDiane study by the end of 2008 with known 
renal or diabetic retinopathy status. A total of 579 participants were excluded because 
of unclear data regarding their exact alcohol consumption, and 141 were excluded 
because of unclear data regarding the of type beverage consumed. Data regarding 
alcohol consumption in g per week were available for 3608 participants, and data 
regarding the type of beverage consumed were available for 3467 participants 
(including abstainers). A more detailed description of the study population is given in 




4.2 Study II 
 
The second study is a prospective study that included 4269 participants, with known 
renal status at baseline who had enrolled in the FinnDiane study by the end of 2012. 
Exclusion criteria were prevalent ESRD at baseline (359 participants), unclear data 
regarding smoking status (293 participants), unclear data regarding smoking in pack-
years (202 participants), and unclear follow-up data regarding renal status (4 
participants). The final cohort comprised 3613 participants with known smoking status 
and 3411 participants with known pack-year data. The baseline characteristics of the 
study population are given in Table 3.   
 
4.3 Study III 
 
The third study is a prospective study that included 4269 participants who had enrolled 
in the FinnDiane study by the end of 2012 with known renal status. Participants with 
unclear data regarding smoking status (338), unclear data regarding the risk allele of 
interest (1306 participants), and unclear follow-up data regarding ESRD (4 participants) 
were excluded from the study. The final cohort comprised 2621 participants. Patient 
characteristics of the study population are presented in Table 3. 
  
4.4 Study IV 
 
The fourth study is a prospective study that included 4771 participants who had 
enrolled in the FinnDiane study by the end of 2013. Participants with unclear smoking 
status (261 participants), unclear data regarding smoking in pack-years (252 
participants), unclear data regarding smoking intensity (83 participants), or unclear 
data regarding the follow-up of CVD outcomes (4 participants) were excluded. The final 
cohort comprised 4506 participants with known smoking status, 4254 participants with 
known pack-year data, and 4423 participants with known data regarding the intensity 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.1 Anthropometric measurements, body mass index, and blood 
pressure 
 
During the study visit, body weight was measured while wearing light clothing and 
registered to the closest 0.1kg, and height was registered to the closest 1 cm. BMI was 
calculated as body weight divided by height squared (kg/m2). Waist circumference was 
measured midway between the lowest rib and the iliac crest and, hip circumference 
was measured at the level of the major trochanters of the femurs. WHR was calculated 
by dividing the waist circumference by the hip circumference. Blood pressure was 
measured twice at 2-min intervals in a supine position after a 10-min rest using a 
mercury sphygmomanometer or an automated standardized blood pressure device. 
The mean of these measurements was then calculated and used in the analyses. 
Hypertension was defined as SBP >140 mmHg or DBP >90 mmHg or known blood 
pressure medication based on the Drug Prescription and Drug Reimbursement 
Registers. 
 
5.2 Laboratory measurements   
 
HbA1c values were measured locally at each study center by standardized assays and 
were reported in both mmol/mol and percentages. Insulin sensitivity was determined 
by the eGDR, that was calculated with an equation modified for the use of HbA1c instead 
of HbA1: eGDR = 24.4 − 12.97 x WHR − 3.39 x AHT − 0.60 x HbA1c, where AHT stands for 
antihypertensive treatment or blood pressure ≥140/90 mmHg (yes = 1, no = 0) (131). 
Serum lipids and lipoproteins were measured centrally in the Professor Marja-Riitta 
Taskinen’s laboratory at the research laboratory of the Helsinki University Central 
Hospital. Serum creatinine concentrations were also measured centrally from the blood 






5.3 Definition of diabetic nephropathy and assessment of renal function 
 
The diagnosis of diabetic nephropathy was defined as macroalbuminuria (albumin 
excretion rate >200 µg/min or >300 mg/24 h) or ESRD. UAER was determined at a 
central laboratory from timed overnight or 24-h urine collections by radioimmunoassay 
(Pharmacia, Uppsala, Sweden) until 2002 and thereafter by an immunoturbidimetry 
method (Hitachi 911 analyzer, Roche Diagnostics, Hoffman-La Roche, Basel 
Switzerland). Based on at least two out of three UAER measurements, the participants 
were divided into three different classes: normoalbuminuria (UAER less than 20 µg/min 
or 30 mg/24 h), microalbuminuria (UAER ≥ 20 <200 µg/min or ≥30 <300 mg/24 h), and 
macroalbuminuria (UAER ≥200 µg/min or ≥300 mg/24 h). ESRD was defined as 
participants receiving dialysis treatment or having undergone kidney transplantation. 
Any progression in diabetic nephropathy included progression from normoalbuminuria 
to microalbuminuria, from normoalbuminuria or microalbuminuria to 
macroalbuminuria, or from a lower renal stage to ESRD. Renal function was estimated 
by eGFR calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation (54). 
In Study I, the diabetic nephropathy status was defined at baseline. In Study II and Study 
III, the follow-up data for diabetic nephropathy and ESRD were based on the medical 
records and on the Finnish Care Register for Health Care maintained by the National 
Institute for Health and Welfare that includes all dates for hospital admissions and 
discharges and diagnoses for the care periods. Follow-up data were also obtained from 
the Cause of Death Register based on the data from death certificates. For ESRD, the 
following International Classification of Diseases (ICD) codes were used: ICD-10: Z940, 
T824, Z992, Y841 and T861 (http://apps.who.int/classifications/icd10/browse/ 
2016/en) and the following procedure codes based on the Nordic Medico-Statistical 
Committee: KAS10, KAS20, KAS40, KAS60, KAS61, TJA33, TJA35, TK800 and TK820 (since 
1996 http://nordclass.se/ncsp_e.htm). 
 
5.4 Definition of severe diabetic retinopathy 
 
Diabetic retinopathy status was recorded during baseline visits using questionnaires 
completed by a health care professional (attending physician or diabetes nurse). The 
questionnaires included data regarding the level of diabetic retinopathy and the time 
of diagnosis and possible laser treatment. In Study I, severe diabetic retinopathy was 




5.5 Definition of coronary heart disease, heart failure, and stroke 
 
In Study IV, follow-up data for incident CHD, heart failure and stroke events were based 
on the Finnish Care Register for Health Care or the Cause of Death Register. The 
following ICD and other codes were used for CHD: myocardial infarction ICD-8/9: 410 
(www.icd9data.com/2007/Volume1) or ICD-10: I21–22 (http://apps.who.int/classify-
cations/icd10/browse/2016/en) or coronary intervention codes for coronary artery 
bypass surgery or balloon angioplasty, procedure codes based on the Nordic Medico-
Statistical Committee: TFN40, FN1AT, FN1BT, FN1YT, FNF, FNG, FNA, FNB, FNC, FND 
and FNE (since 1996 http://nordclass.se/ncsp_e.htm) and surgical procedure codes 
according to the procedure classification of the Finnish Hospital Association 1983–
1995: 5311– 5315 (348); heart failure ICD-8: 4270, 4271, 7824, ICD-9: 4280–4289, ICD-
10: I50; and ischemic/ hemorrhagic stroke ICD-8/9: 430–434, ICD-10: I60–I64. 
 
5.6 Assessment of lifestyle factors 
 
5.6.1 Alcohol consumption 
 
At the baseline visit, all participants were asked to fill in questionnaires regarding their 
alcohol consumption. Participants reported their weekly consumption of different 
beverage types, namely beer (one third of a liter bottles), wine (glasses), and stronger 
spirits (deciliters). The amount of alcohol consumed was first transformed into 
standard drinks that contain 12 g of pure alcohol. The equivalent dose for one standard 
drink is 33 cl beer, 12 cl wine, and 4 cl spirits. The total alcohol consumption in g per 
week was then calculated. In Study I, the participants were grouped in five different 
groups based on their weekly alcohol consumption—abstainers, light consumers, 
moderate consumers, heavy consumers, and former consumers, who no longer were 
consuming alcohol.  
There is no international consensus regarding the different levels of alcohol 
consumption, and therefore the limits were based on the Finnish Current Care 
guidelines from 2011 (www.kaypahoito.fi). The limit of heavy drinking was ≥7 doses (84 
g) per single time or ≥ 24 doses (288 g) per week for men and ≥5 doses (60 g) per single 
time or ≥16 doses (192 g) per week for women. The limit for a light consumer was 
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defined as <7 doses per week for men and <5 doses per week for women. Moderate 
consumers were consuming more than light drinkers but less than the weekly heavy 
drinking limits. 
In Study I, participants were also grouped based on the beverage type they were mainly 
consuming. If a participant were consuming one type of beverage ≥75% of the total 
consumption in g/week, they were considered wine, beer, or spirit consumers; 




During the baseline visit, participants were asked to fill in questionnaires regarding 
their current and former smoking habits. Based on the FinnDiane protocol, the 
participants were considered smokers if they had smoked at least one cigarette per day 
for at least one year. Otherwise, they were considered never smokers. Participants who 
had stopped smoking before their baseline visit were considered former smokers. 
Data regarding the participants’ smoking habits were also assessed during the 
prospective visits and through a mailed questionnaire in 2015. Additional smoking data 
from prospective visits were available for 1566 participants and data from the follow-
up questionnaire were available for nearly 2000 individuals. Based on these data, the 
baseline smoking status was corrected for 46 participants and missing smoking status 
was reconstructed for 118 participants. These additional smoking data were available 
in Study IV. 
The percentages of current smokers at the baseline visits and in the 2015 follow-up 
questionnaire are shown in Figure 2. During the last 20 years, the proportion of men 
who were current smokers at the baseline visit declined from 30.6% in 1994–1998 to 
19.7% in 2010–2014. For women, the percentage of current smokers started to decline 
only during the last 10 years from 24.4% in 2003–2004 to 17.0% in 2010–2014. Based 
on the follow-up questionnaire sent to the participants in 2015, only 9.9% of men and 
9.3% of women were current smokers. However, the participants who answered the 
questionnaire were older (median age 52.5) than the participants who enrolled in the 
FinnDiane study during the years 2010–2014 (median age 37.9). 
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Figure 2. Percentage of current smokers at the baseline visits and according to the follow-up 
questionnaire in 2015 
 
Questionnaires also included questions about the year a participant started smoking 
and the year of smoking cessation if a participant was a former smoker or had several 
different time periods of smoking. Participants were also asked to report the number 
of cigarettes per day they smoked during different time periods. 
Based on this information, the cumulative smoking in pack-years was calculated for 
each participant. By definition, smoking 20 cigarettes per day in a period of one year, 
equals one pack-year. The pack-year data were used in Study II and Study IV. Study IV 
also used the intensity of smoking as cigarettes per day and packs (20 cigarettes) per 
















Figure 3. Cumulative smoking in pack-years (median, IQR) in current and former smokers at 
baseline visit  
 
Figure 3 shows the average cumulative smoking in pack-years for current and former 
smokers at baseline. Men who were current smokers had smoked 14 pack-years and 
women who were current smokers had smoked 9 pack-years. Among former smokers, 
the corresponding numbers were 11 for men and 4.5 for women. Figure 4 shows the 
average intensity of smoking in cigarettes per day in current and former smokers at 
baseline. Among current smokers, men were smoking 15 cigarettes per day and women 
10. In former smokers, the intensity of smoking was 18 cigarettes per day in men and 
10 in women. The median age when the participants started smoking was 17 
(interquartile range [IQR]) 15–20), which was the same for men and women and also 
for current and former smokers. The median age of smoking cessation was 33 (IQR 26–
41) for men and 28 (IQR 23–36) for women. 
Figure 4. Intensity of smoking in cigarettes per day (median, IQR) in current and former smokers 



































For Study III, the genetic variant rs4972593 was extracted from an existing GWAS. The 
genotyping was performed with the Illumina 610Quad chip, and the quality control and 
genotype imputation was based on the HapMapII CEU population. The imputed 
genotype probabilities of rs4972593 were converted to the most likely genotypes using 
a probability threshold of 0.9 for genotype calling. After the conversion, the genotype 
call rate was 0.98, the minor A allele frequency was 0.11, and no deviation from the 
Hardy–Weinberg disequilibrium was observed (p=0.72). The imputation quality of 
rs4972593 was good (MACH: quality=0.99, Rsq=0.95). For Study III, data for the 
genotype, smoking history, and ESRD were available for 2621 patients. 
 
5.8 Statistical analyses 
 
In Study I, Study II, and Study IV, data regarding baseline characteristics are presented 
as means ± standard deviation for normally distributed values and otherwise as 
medians (IQR). Categorical variables are reported as percentages. Differences between 
groups were analyzed using ANOVA for normally distributed continuous variables and 
otherwise using the Kruskal–Wallis test. Differences between categorical variables 
were analyzed using the χ2 test. In all studies, the statistical analyses were performed 
with IBM SPSS statistics versions 22–24 (IBM Corporation, Armonk, NY, USA) and SAS 
versions 9.2–9.4 (SAS Institute, Cary, NC, USA).  
 
5.8.1 Study I 
 
The cross-sectional associations between alcohol consumption or beverage type and 
diabetic nephropathy or severe diabetic retinopathy were calculated with logistic 
regression analyses, providing odds ratios (OR) with 95% confidence intervals (CI). The 
covariates included in the multivariable models were age at onset of diabetes, sex, 
duration of diabetes, triglycerides, HDL cholesterol, HbA1c, social class, BMI, smoking 
status, hypertension, and lipid-lowering medication. In the second model eGDR was 
included and HbA1c, BMI, and hypertension were excluded. The interaction term 
between sex and amount of alcohol consumed or beverage type was entered into the 
models, and if the interaction term was significant the analyses were performed 
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separately for men and women. Light consumers and wine drinkers were used as 
reference categories in the analyses. 
 
5.8.2 Study II 
 
The 12-year cumulative incidence of micro- and macroalbuminuria among the 
participants with different baseline smoking status was estimated using the Kaplan–
Meier method. A log-rank test was used to test the differences between the groups. 
Fine and Gray´s test with death as the competing risk was used when analyzing the 12-
year cumulative risk of ESRD. Cox regression models were used for the analyses 
regarding cumulative smoking, measured with pack-years as the continuous variable, 
providing hazard ratios (HRs) with a 95% CI for the development of different stages of 
diabetic nephropathy. Cox regression models were also used in analysing the combined 
risk of any progression of diabetic nephropathy and the risk of ESRD associated with 
baseline smoking status. The variables included in the stepwise models were sex, 
duration of diabetes, HbA1c, SBP, HDL cholesterol and triglycerides, BMI, and social 
class. In former smokers, the effect of smoking cessation was analyzed using the years 
between quitting and the baseline visit as a continuous variable in the Cox regression 
models. Cubic spline graphs were used to estimate the association between continuous 
pack-years and the risk of any diabetic nephropathy and ESRD. 
 
5.8.3 Study III 
 
The combined effect of history of smoking (never vs. ever) and the rs4972593 variant 
on the 40-year cumulative risk of ESRD was estimated using the Kaplan–Meier method. 
A log-rank test was used to test the differences between the groups. Cox regression 
models were also used, providing HRs for the risk of ESRD. The third-degree interaction 
term between sex, smoking, and the minor allele was significant with respect to the 
development of ESRD (p=0.001), indicating that the effect of the rs4972593 on the 
progression of ESRD is dependent on smoking status and is different for men and 





5.8.4 Study IV  
 
In Study IV, the effect of smoking status, cumulative smoking in pack-years, and 
smoking intensity in packs per day were analyzed using Cox regression models, 
providing HRs with 95% CI for the incidence of CHD, heart failure and stroke. Possible 
confounding factors were included in the models in different steps and combinations. 
These included environmental risk factors (social class and alcohol intake) and 
traditional CVD risk factors (age, sex, HbA1c, hypertension, duration of diabetes, BMI, 
HDL cholesterol, triglycerides, and baseline presence of diabetic nephropathy). The 
interaction term between sex and smoking status, intensity of smoking, and cumulative 
smoking was entered into the models, and if the interaction term was significant the 
analyses were performed separately for men and women. Finally, the results regarding 
the risk of CHD and stroke were combined with those of previous studies in a small 



















6.1 Alcohol consumption and the risk of diabetic nephropathy and 
severe diabetic retinopathy (Study I) 
 
At baseline, 858 of the 3608 participants were abstainers, 1690 were light consumers 
of alcohol, 799 were moderate consumers, 120 were heavy consumers, and 141 were 
former consumers. The proportions of some of these groups differed between men and 
women (Figure 5). The percentage of abstainers was higher (31.8%) among women 
compared to men (16.5%, p <0.0001). The proportion of light consumers was similar 
among men (47.0%) and women (46.6%). Percentages of moderate consumers (27.5% 
vs. 16.2% p <0.0001) and heavy consumers (5.1% vs. 1.4%, p <0.0001) were higher 
among men compared with women. The proportion of former consumers did not differ 
between genders (3.9% in both). 
Figure 5. Proportion of abstainers and light, moderate, heavy, and former consumers 














Among the participants who were current consumers of alcohol, the number of wine 
consumers was 322, the number of beer consumers was 1245, the number of spirit 
consumers was 175, and the number of mixed drinkers was 867. Figure 6 shows the 
baseline percentages of participants consuming different beverage types in men and 
women. There were fewer wine consumers among men (4.6%) compared to women 
(22.9%, p <0.0001). Otherwise, there were more beer (50.7% vs. 43.8%, p <0.001), spirit 
(8.4% vs. 4.5%, p <0.0001), and mixed consumers (36.4% vs. 28.9%, p <0.0001) among 
men compared to women. 
Figure 6. Proportion of wine, beer, spirit, and mixed consumers at baseline in men and 
women 
Baseline characteristics differed between the groups. Heavy consumers were the oldest 
and had the highest total cholesterol and triglyceride concentrations and the highest 
blood pressure. HDL cholesterol was the highest among moderate and heavy 
consumers. Former consumers had the longest duration of diabetes and the poorest 
glycemic control. Among current alcohol consumers, spirit drinkers were the oldest and 
had the longest duration of diabetes and the poorest lipid profile.  
The prevalence of diabetic nephropathy (i.e. macroalbuminuria or ESRD) at baseline is 
presented in Figure 7. The percentage of participants with diabetic nephropathy was 
the lowest in light consumers of alcohol (17.6%) and the highest in former consumers 
(45.4%). In addition, the prevalence of severe diabetic retinopathy was the lowest in 
light consumers (29.6%) and the highest in former consumers (52.2%) (Figure 8). 














Figure 7. Baseline prevalence of diabetic nephropathy stratified by the amount of 
alcohol consumed 






















The prevalence of diabetic nephropathy differed between men and women in different 
groups based on beverage types. Beer-drinking men had the lowest prevalence of 
diabetic nephropathy (16.7%), but in women the prevalence of diabetic nephropathy 
was similar for wine drinkers (12.6%), beer drinkers (13.8%), and mixed drinkers 
(14.2%). Spirit drinkers had the highest prevalence of diabetic nephropathy in both men 
(45.0%) and women (23.4%) (Figure 9).  The prevalence of severe diabetic retinopathy 
was highest in spirit drinkers (52%) (Figure 10).  
 
Figure 9. Baseline prevalence of diabetic nephropathy stratified by beverage type in 
men (a) and women (b) 































Table 4 presents the results of the logistic regression analyses regarding the association 
between the amount of alcohol consumed and diabetic nephropathy and severe 
diabetic retinopathy. Compared with light consumers, former drinkers had the highest 
risk of diabetic nephropathy with an OR of 2.44 (95% CI 1.49–3.99), adjusted for age at 
onset of diabetes, sex, duration of diabetes, triglycerides, HDL cholesterol, HbA1c, social 
class, BMI, smoking status, hypertension, and lipid-lowering medication. Abstainers 
had a higher risk of diabetic nephropathy with an OR of 1.39 (95% CI 1.05–1.84) 
compared with light consumers. The risk of diabetic nephropathy in moderate and 
heavy consumers did not differ from that in light consumers. The results regarding the 
risk of severe diabetic retinopathy were similar, with a higher risk in former drinkers 
[OR 1.73 (95% CI 1.07–2.79)] and abstainers [OR 1.42 (95% CI 1.11–1.82)] compared 
with light consumers. In the model including the eGDR, the results for the risk of 
diabetic nephropathy did not change significantly, and former drinkers [2.18 (95% CI 
1.29–3.69)] and abstainers [1.39 (95% CI 1.04–1.87)] still had a higher risk compared 
with light consumers. However, regarding the risk of severe diabetic retinopathy, the 
results in former drinkers were attenuated, and when eGDR was included in the model 
only the abstainers had a significantly higher risk compared with light consumers. 
Table 4. Odds ratios for the risk of diabetic nephropathy and severe diabetic retinopathy according to 
alcohol consumption 
 n cases OR1 (95% CI) P value OR2 (95% CI) P value 
Nephropathy       




749 157 0.97 (0.73–1.29) 0.822 0.87 (0.65–1.18) 0.378 
 Heavy consumers 110 23 0.77 (0.41–1.44) 0.404 0.58 (0.31–1.10) 0.093 
 Former drinkers 130 59 2.44 (1.49–3.99) <0.001 2.18 (1.29–3.69) <0.01 
 Abstainers 811 199 1.39 (1.05–1.84) <0.05 1.39 (1.04–1.87) <0.05 
Severe retinopathy       




797 257 0.94 (0.74–1.21) 0.648 0.91 (0.71–1.18) 0.486 
 Heavy consumers 120 42 0.91 (0.53–1.55) 0.715 0.84 (0.49–1.44) 0.527 
 Former drinkers 137 71 1.73 (1.07–2.79) <0.05 1.51 (0.92–2.49) 0.102 
 Abstainers 854 323 1.42 (1.11–1.82) <0.01 1.43 (1.11–1.84) <0.01 
OR1: Adjusted for age at onset, sex, smoking, duration of diabetes, triglycerides, HDL cholesterol, social 
class, HbA1c, hypertension, BMI, and lipid-lowering medication  
OR2: Adjusted for age at onset, sex, smoking, duration of diabetes, triglycerides, HDL cholesterol, social 
class, lipid-lowering medication, and estimated glucose disposal rate (eGDR) 
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Table 5 presents the results of the logistic regression analyses regarding the association 
between the beverage type and diabetic nephropathy and severe diabetic retinopathy. 
The interaction term between sex and beverage type was significant for the risk of 
diabetic nephropathy; therefore, men and women were analyzed separately. 
Compared with wine consumers, spirit-drinking men had a higher risk of diabetic 
nephropathy with an OR of 2.80 (95% CI 1.15–6.81). In women, no significant difference 
was found between those consuming different types of beverages regarding the risk of 
diabetic nephropathy. Regarding the risk of severe diabetic retinopathy, there was no 
interaction between sex and type of beverage. Therefore, men and women were 
pooled for the analysis. Spirit consumers had a higher risk of severe diabetic 
retinopathy with an OR of 2.32 (95% CI 1.35–4.00) compared with wine consumers. 
Regarding the risk of severe diabetic retinopathy, no difference between wine and beer 
consumers or mixed consumers was observed. When eGDR was entered into the 
models, the risk of diabetic nephropathy in spirit-drinking men and the risk of severe 
diabetic retinopathy in all spirit consumers was no longer significantly higher compared 
with wine consumers. 
Table 5. Odds ratios for the risk of diabetic nephropathy and severe diabetic retinopathy according to 
beverage type 
  n cases OR1 (95% CI) P value OR2 (95% CI) P value 
Nephropathy 
men 
            
  Wine 65 16 Reference    Reference   
  Beer 714 119 0.83 (0.37–1.82)  0.632 0.71 (0.32–1.59)  0.407 
  Spirits 120 54 2.80 (1.15–6.81)       0.023 2.34 (0.96–5.71)  0.062 
  Mixed 521 127 1.33 (0.60–2.92)  0.481 1.09 (0.50–2.38)  0.834 
Nephropathy 
women 
            
 Wine 238 30 Reference  Reference  
  Beer 464 64 1.22 (0.65–2.31)  0.536 1.12 (0.59–2.12)  0.730 
  Spirits 47 11 0.84 (0.26–2.69)  0.766 0.64 (0.21–2.03)  0.455 
  Mixed 296 42 0.96 (0.48–1.91)  0.897 0.80 (0.40–1.59)  0.527 
Severe 
retinopathy 
      
  Wine 321 95 Reference    Reference   
  Beer 1241 327 1.26 (0.86–1.84) 0.246 1.09 (0.74–1.61) 0.664 
  Spirits 176 90 2.32 (1.35–4.00) 0.002 1.69 (0.97–2.94) 0.063 
  Mixed 866 284 1.32 (0.89–1.97) 0.166 1.08 (0.73–1.60) 0.712 
OR1: Adjusted for age at onset, sex, smoking, duration of diabetes, triglycerides, HDL cholesterol, social 
class, HbA1c, hypertension, BMI, and lipid-lowering medication  
OR2: Adjusted for age at onset, sex, smoking, duration of diabetes, triglycerides, HDL cholesterol, social 
class, lipid-lowering medication, and estimated glucose disposal rate (eGDR) 
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6.2 Smoking and the risk of diabetic nephropathy (Study II) 
 
Among the 3613 participants, diabetic nephropathy status progressed in 198 (23.0%) 
current smokers, 133 (19.6%) former smokers, and 219 (12.4%) never smokers during 
a median follow-up of 6.8 (IQR 4.3–10.6) years. Altogether, 99 (10.6%) current smokers, 
79 (10.7%) former smokers, and 115 (5.9%) never smokers developed ESRD during a 
follow-up of 12.2 (IQR 10.0–14.0) years. Current smokers had the poorest glucose 
control and were more insulin-resistant compared with the others. Former smokers 
were the oldest and had the longest duration of diabetes, and never smokers had the 
most favorable lipid profile.  
 
Table 6 presents the Cox regression models for the progression of diabetic nephropathy 
and the development of ESRD. Current smokers had a higher risk of any progression of 
diabetic nephropathy with a HR of 1.46 (95% CI 1.17–1.83) compared with never 
smokers after adjustments for sex, duration of diabetes, HbA1c, SBP, HDL cholesterol, 
triglycerides, BMI, and social class. The risk of ESRD was higher in current smokers with 
a HR of 1.42 (95% CI 1.04–1.95) compared with never smokers. The risk of any 

















Progression         
     Never 1766 219 Reference  Reference  Reference  




















ESRD         
   Never 1946 115 Reference  Reference  Reference  




















HR1: Adjusted for sex, duration of diabetes, HbA1c, and systolic blood pressure 
HR2: Adjusted for sex, duration of diabetes, HbA1c, systolic blood pressure, HDL cholesterol, triglycerides, 
and BMI 
HR3: adjusted for sex, duration of diabetes, HbA1c, systolic blood pressure, HDL cholesterol, triglycerides, 




progression or of ESRD in former smokers compared with never smokers did not differ 
significantly after adjustments for other covariates.    
When the association between the cumulative smoking dose in pack-years and the risk 
of different stages of diabetic nephropathy were assessed, current smokers had a 
higher risk of macroalbuminuria with a HR of 1.025 (95% CI 1.010–1.041) per each pack-
year and a higher risk of ESRD with a HR of 1.041 (95% CI 1.001–1.026) compared with 
never smokers. Former smokers had a higher risk of microalbuminuria with a HR of 
1.034 (95% CI 1.014–1.054) per pack-year compared with never smokers, but the risk 
of macroalbuminuria and ESRD was similar. 
In former smokers, the risk of macroalbuminuria decreased by 7% per each year 
without smoking before the baseline visit. When former smokers were grouped in 5-
year intervals based on the time since quitting before baseline, the risk was similar in 
former smokers compared with current smokers when they quit smoking less than 5 
years before baseline. However, with increasing years since smoking cessation, the risk 
approached the risk seen in never smokers (as shown in Figure 11) based on Cox 
regression models adjusted for sex, duration of diabetes, and HbA1c. 
 
Figure 11. Cumulative risk of any progression of diabetic nephropathy during follow-up based 
on smoking status and years since smoking cessation before baseline in former smokers 
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6.3 The combined effect of smoking and the rs4972593 allele on the 
development of end-stage renal disease (Study III) 
 
The follow-up of Study III ended in 2013, and by then 36 (24.7%) non-smoking women 
with the rare allele rs4972593 had developed ESRD compared with 66 (10.8%) non-
smoking women without the rare allele (Table 7a). In men, the results were the 
opposite; by 2013, 14 (11.8%) non-smoking men with the rare allele had developed 
ESRD compared with 104 (21.4%) non-smoking men without the rare allele (Table 7b). 
In women, the time period from diagnosis of diabetes to ESRD was longer, and the age 
at ESRD diagnosis was higher in non-smokers without the rare allele compared to non-
smokers with the rare allele (Table 7a). Again, in men the findings were the opposite, 
and the time period to ESRD was longer and the age at ESRD diagnosis was higher in 
non-smokers with the rare allele (Table 7b). Among smokers, there were no differences 
between the groups. 
Table 7a. Participant characteristics according to smoking status and rs4972593 allele for women 













n 121 428 146 609   
ESRD 2013 (%) 26.4 19.6 24.7 10.8 0.105 <0.0001 
Time period to 
ESRD (years) 
34 (28–42) 34 (28–43) 35 (28–43) 37 (31–45) 0.871 0.009 
Age at the ESRD 
diagnosis (years) 
49 (40–57) 49 (41–58) 47 (38–56) 51 (43–60) 0.519 0.002 
       
Table 7b. Participant characteristics according to the smoking status and rs4972593 allele for men 











 rare allele 
n 148 565 119 485   
ESRD 2013 (%) 33.8 28.1 11.8 21.4 0.179 0.017 
Time period to 
ESRD (years) 
36 (30–42) 35 (28–42) 37 (31–45) 35 (28–42) 0.510 0.005 
Age at the ESRD 
diagnosis (years) 
50 (42–60) 52 (42–60) 52 (45–59) 49 (40–58) 0.677 0.031 
Values are presented as median (IQR) or percentages. P-values were obtained using a Kruskal–Wallis test 




The 40-year cumulative risk of ESRD was 27.1% (95% CI 20.6–33.1) in non-smoking 
women with the minor allele compared with 10.5% (95% CI 7.9–13.0) in non-smoking 
women without the minor allele (p <0.0001, HR 2.62 [95% CI 1.74–3.93]). In women 
who were ever smokers, the minor allele carriers had around a 10% higher 40-year 
cumulative risk of ESRD [32.9% (95% CI 25.6–40.0)], but the difference was not 
significant compared with women without the minor allele [23.4% (95% CI 19.4–27.1)] 
(p=0.117). 
In non-smoking men, the effect of the minor allele was the opposite. In non-smoking 
men with the minor allele, the 40-year cumulative risk of ESRD was 12.3% (95% CI 5.9–
18.4) compared to 24.6% (95% CI 20.9–28.1) in non-smoking men without the minor 
allele (p=0.007, HR 0.47 [95% CI 0.27–0.82]). In men who were ever smokers, the minor 
allele did not alter the cumulative risk of ESRD. Smoking men with the minor allele had 
a 31.8% (95% CI 25.5–37.6) cumulative risk of ESRD compared with a 32.0% cumulative 
risk (95% CI 28.8–35.0) (p=0.336) in smoking men without the minor allele.  
 
6.4 Smoking and the risk of coronary heart disease, heart failure, and 
stroke (Study IV) 
 
Among the 4506 participants, 130 (11.6%) current smokers, 139 (14.8%) former 
smokers, and 243 (10.7%) never smokers developed CHD during the follow-up. The 
respective numbers for heart failure were 72 (6.3%), 110 (10.9%), and 131 (5.7%). For 
any stroke in men, the respective numbers were 63 (9.8%), 75 (13.2%), and 53 (5.0%), 
and for any stroke in women the respective numbers were 27 (5.6%), 20 (5.0%), and 66 
(5.3%).  
Figure 12 presents the age and sex-adjusted cumulative risk of CVD based on baseline 
smoking status. Current smokers had a higher risk of CHD with a HR of 1.31 (95% CI 
1.05–1.63), but in former smokers the risk of CHD was similar to that in never smokers, 
with a HR of 1.10 (95% CI 0.89–1.36) (Figure 12a). In contrast, the risk of heart failure 
was higher in current smokers with a HR of 1.43 (95% CI 1.07–1.92) and in former 
smokers with a HR of 1.52 (95% CI 1.17–1.96) (Figure 12b). In men, the risk of any stroke 
was also higher in current smokers with a HR of 2.20 (95% CI 1.52–3.17) and in former 
smokers with a HR of 2.06 (95% CI 1.45–2.95) compared with never smokers (Figure 
12c). However, in women the risk of any stroke did not differ between the groups; for 
current smokers the HR was 1.32 (95% CI 0.84–2.08), and for former smokersit was 0.89 






















Figure 12. Age and sex adjusted cumulative risk of coronary heart disease (CHD) (a), 
heart failure (b), any stroke in men (c) and any stroke in women (d) during the follow-







After further adjustments for other cardiovascular risk factors, the risk of CHD in 
current smokers, and the risk of heart failure in current and former smokers was 
attenuated, and after the lipid variables were added into the model, the difference 
compared with never smokers was no longer statistically significant. However, in men 
who were current or former smokers the risk of any stroke remained significantly 
higher, as it did after adjustments for other CVD risk factors, including lipids. Notably, 
in men the risk of stroke was increased even after diabetic nephropathy was included 
in the model, with a HR of 1.90 (95% CI 1.29–2.82) for current smokers and of 1.92 (95% 
CI 1.32–2.80) for former smokers. 
When the effect of intensity of smoking in packs per day on the risk of different CVD 
outcomes was assessed, the risk of CHD increased, with a HR of 1.28 (95% CI 1.00–1.63) 
in current smokers per one pack per day. The risk of heart failure was also higher in 
current and former smokers compared with never smokers, but after the results were 
adjusted for the lipid variables the difference was no longer statistically significant. The 
risk of any stroke increased with a HR of 1.50 (95% CI 1.09–2.05) with intensity of one 
pack per day in current smokers and a HR of 1.45 (95% CI 1.10–1.90) in former smokers 
compared with never smokers. 
When addressing the CVD risk associated with cumulative smoking in pack-years, the 
risk of CHD in current smokers and heart failure in current and former smokers 
increased by 1–1.5% per each pack-year. Again, the effect of cumulative smoking was 
stronger on the risk of stroke, which increased by 1.5–2% per one pack-year in both 
current and former smokers.  
In a small meta-analysis, the results from Study IV were combined with the results of 
three other studies regarding the risk of CHD and one other study regarding the risk of 
stroke. Based on the results, the risk of CHD was higher in current smokers with a risk 
ratio (RR) of 1.36 (95% CI 1.07–1.72), and the risk of stroke was increased in men with 
a RR of 1.77 (95% CI 1.00–3.14) in current smokers and with a RR of 2.13 (95% CI 1.52–










7.1 Effect of alcohol consumption and beverage type on the risk of 
diabetic nephropathy and severe diabetic retinopathy 
 
Study I showed that in former alcohol consumers the risk of diabetic nephropathy was 
doubled, and the risk of severe diabetic retinopathy was 50–70% higher compared with 
light consumers. In abstainers, the risk of diabetic nephropathy and severe diabetic 
retinopathy was around 40% higher compared with light consumers. However, the risk 
of diabetic nephropathy or severe diabetic retinopathy was not increased in current 
moderate or heavy consumers compared with light consumers. When the comparison 
was made between different beverage types, a higher risk of diabetic nephropathy was 
seen only in men who were spirit drinkers, but the risk of severe diabetic retinopathy 
was higher in all spirit drinkers. 
The EURODIAB study showed an association between moderate alcohol consumption 
and a decreased risk of microvascular complications in people with type 1 diabetes 
(332). The study used abstainers as a reference group and only observed a trend 
towards a lower risk in moderate consumers. However, the actual risk of different 
microvascular outcomes was not significantly higher in heavier consumers compared 
with participants with lower alcohol consumption. Thus, the results are in line with 
those of Study I. An older cross-sectional report from the WESDR showed an inverse 
association between alcohol consumption and the prevalence of proliferative diabetic 
retinopathy (334). However, a later WESDR prospective study did not find any 
association between alcohol consumption and the incidence or progression of diabetic 
retinopathy (335). It is of note that in the prospective WESDR study, alcohol 
consumption was analyzed as a continuous variable. This approach does not necessarily 
provide information on different alcohol consumption levels, considering the 
previously known non-linear association between alcohol consumption and vascular 
complications. In the DCCT/EDIC study, occasional or regular drinking was not 
associated with a higher risk of proliferative diabetic retinopathy compared with 
abstaining (168). In addition, in Study I the risk of diabetic nephropathy or severe 
diabetic retinopathy seems to stay at a similar level regardless of the amount of alcohol 
consumed. A similar L-shaped curve is also seen in studies regarding alcohol 
consumption and the risk of CHD in people with type 2 diabetes (327). However, in the 
general population, this L-shaped association between alcohol consumption and CHD 
is only seen in men (324). In Study I, men and women were pooled because there was 
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no significant interaction between sex and the amount of alcohol consumed and the 
risk of diabetic nephropathy or severe diabetic retinopathy. However, the number of 
women who were heavy consumers was clearly lower compared to men (24 or 1.4% 
vs. 96 or 5.1%), and therefore the risk of diabetic nephropathy and severe diabetic 
retinopathy in heavy consumers refers mostly to the risk seen in men.  
In Study I, former consumers of alcohol carried the highest risk of diabetic nephropathy 
and severe diabetic retinopathy. In the WESDR study, former drinkers had a higher 
prevalence of proliferative diabetic retinopathy compared with current drinkers, which 
is in line with results of Study I. Other studies regarding people with type 1 diabetes, 
including the EURODIAB and the prospective WESDR study, did not report results for 
former drinkers separately. In these studies, the former drinkers were combined with 
the life-long abstainers, probably leading to a higher risk seen in abstainers. Therefore, 
the results of Study I are not directly comparable with those of most of the previous 
microvascular studies. However, the results are in line with the previous CHD studies 
that have reported a higher CHD risk in former drinkers (323, 325). It is important to 
separate the former drinkers from the abstainers to avoid the “sick quitter effect”. In 
addition, in Study I the former consumers of alcohol had the poorest glycemic control 
and were more insulin-resistant with the highest insulin dose, and together with the 
heavy consumers they also had the lowest eGDR level. Former consumers were more 
often taking anti-hypertensive or lipid-lowering medication, and they also had the 
highest percentage of prevalent CVD. Therefore, it is likely that not only the previous 
alcohol consumption but the overall impaired health status in former consumers has a 
detrimental effect on the risk of microvascular complications.   
The risk of diabetic nephropathy and severe diabetic retinopathy was also addressed in 
the individuals drinking different alcoholic beverages. Regarding the risk of diabetic 
nephropathy, men and women were analyzed separately due to the interaction 
between sex and beverage type. Compared with wine consumers, men who were 
consuming mostly spirits had the highest risk of diabetic nephropathy. In women, there 
were no differences in the risk of diabetic nephropathy between the different beverage 
types. However, this might be explained by the lower number of spirit-drinking women 
(49, 4.5%) compared to spirit-drinking men (127, 8.4%) among all alcohol consumers. 
Regarding the risk of severe diabetic retinopathy, there was no significant interaction 
between sex and beverage type, and women and men were analyzed together. Again, 
spirit drinkers had a higher risk of severe diabetic retinopathy compared with wine 
drinkers. No significant difference in the risk of diabetic nephropathy or severe diabetic 
retinopathy or between wine and beer or mixed drinking was observed. 
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To our knowledge, this was the first study to compare the risk of diabetic nephropathy 
or severe diabetic retinopathy between consumers of different beverage types. The 
EURODIAB study did not compare the risk of microvascular complications between 
consumers of different beverage types but only within a specific beverage type; 
therefore, the results of Study I are not directly comparable with their results. However, 
they showed an association between moderate wine consumption and a reduced risk 
of diabetic nephropathy and severe diabetic retinopathy. In addition, moderate beer 
consumption was associated with a lower risk of diabetic nephropathy. In the 
EURODIAB study, spirit consumption was not associated with a significant change in 
the risk of diabetic nephropathy or severe diabetic retinopathy. The results of Study I 
are in line with a large meta-analysis regarding CVD morbidity and mortality (340). 
Based on those results, both wine and beer consumers seemed to have some 
protective effect against CVD, but this effect was not seen in the spirit consumers. 
  
7.2 Mechanisms behind the effect of alcohol consumption and 
beverage type on microvascular complications 
 
Alcohol consumption has known effects on vascular risk factors, such as blood pressure, 
lipids, hemostasis, and inflammation. In Study I, SBP and the HDL level increased with 
the increasing amount of alcohol consumed. Markers for hemostasis were not 
available, but a marker for inflammation, CRP, was lowest among light and moderate 
consumers. In people with diabetes, alcohol also affects glucose metabolism and insulin 
sensitivity. In Study I, wine consumers had the highest eGDR levels and spirit drinkers 
the lowest. When the results for different beverage types were adjusted for insulin 
sensitivity, expressed as eGDR, the difference between wine and spirit drinkers was no 
longer significant. There is some evidence that moderate alcohol consumption, 
especially consumption of red wine, increases insulin sensitivity (313, 318, 349). 
Therefore, the higher risk of diabetic nephropathy in men and risk of severe diabetic 
retinopathy in all individuals who were spirit drinkers might partly be explained by the 
differences in insulin sensitivity between wine and spirit drinkers.  
The lower risk seen in the wine drinkers compared with the spirit drinkers may also 
originate from the differences in socioeconomic status, diet, or other behavioral risk 
factors, such as physical exercise, between the groups. However, the results for 
different beverage types were also significant after adjustments for social class, which 
accounts for at least part of the socioeconomic differences between the groups. 
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Not only the beverage type but also the drinking pattern may explain the higher risk in 
the spirit consumers compared with the wine consumers. Unfortunately, the exact 
information regarding the amount of alcohol the participants consumed per each 
drinking occasion was not available. However, the percentage of heavy consumers was 
higher among spirit drinkers (13.1%) compared with wine drinkers (0.3%, only one 
person). Therefore, it is likely that the percentage of binge drinkers is also higher among 
spirit drinkers. There are no data regarding the association between drinking pattern 
and the risk of microvascular complications, but binge and irregular heavy drinking is 
associated with a higher risk of CHD and stroke (336, 337, 350). Therefore, an 
unfavorable drinking pattern might explain part of the higher risk of diabetic 
nephropathy and severe diabetic retinopathy seen in spirit drinkers compared with 
wine drinkers. 
Even though the risk of diabetic nephropathy or severe diabetic retinopathy did not 
increase with increasing alcohol consumption, people with type 1 diabetes should not 
be encouraged to increase their alcohol consumption due to the known harmful effects 
of alcohol on other health aspects, such as the increased risk of many forms of cancer. 
In people with type 1 diabetes, heavier drinking is also associated with an increased risk 
of hypoglycemia and impaired hypoglycemia awareness, leading to an additional 
detrimental or potentially even lethal effect of heavier alcohol consumption.  
 
7.3 Current smoking and risk of diabetic nephropathy 
 
Current smoking was associated with a 40–50% increased risk of any progression of 
diabetic nephropathy and the development of ESRD. These results are mostly in line 
with many older diabetic nephropathy studies (166, 241, 287-291). In some of these 
studies, the risk of the progression of diabetic nephropathy was up to 2–3 times higher 
in current smokers compared with never smokers. The lower risk increase seen in Study 
II might be explained by the inclusion in the analyses of a wider range of other 
confounding factors. It is of note that many later studies have reported conflicting 
results and have not been able to show a clear association between smoking and the 
development of diabetic nephropathy (82, 215, 244, 286, 292). In the Danish studies, 
this might be explained by a large number of smokers among the study participants and 
the overall smoking (active and passive) prevalence in the population at the time (82, 
292). In addition, some studies did not separate former smokers from either current or 
never smokers (215, 244). 
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Different than the previous diabetic nephropathy studies, the effect of cumulative 
smoking in pack-years on the development of different stages of diabetic nephropathy 
was also analyzed. Compared with never smokers, the risk of macroalbuminuria was 
increased by 2.5% and the risk of ESRD by 1.4% per each pack-year in current smokers. 
The risk of microalbuminuria was also higher in current smokers, but the difference was 
weaker and no longer statistically significant in the final model that included social class 
as a confounding factor. At baseline, there were fewer current smokers who had 
normal UAER compared with the never smokers, 64.6% vs. 75.4%. In addition, the 
percentages of prevalent micro- and macroalbuminuria were higher in the current 
smokers compared with the never smokers. This might explain the weaker association 
with the development of microalbuminuria compared with the effect on later stages of 
diabetic nephropathy. Estimates with continuous pack-year data were also performed, 
showing that after 20–25 pack-years the risk of any progression of diabetic 
nephropathy or ESRD is twice as high in current smokers compared with never smokers.   
  
7.4 The combined effect of smoking and the rs4972593 allele on the 
development of end-stage renal disease 
 
Study III confirmed the previous findings of an increased risk of ESRD in women who 
are carriers of the rs4972593 rare allele. Ever smoking and the rare allele were both 
associated with a 2–3-fold increased risk of ESRD in women. Among smoking women, 
there was no significant difference between the rare and common allele carriers. 
However, there was a trend towards a higher 40-year cumulative ESRD risk in women 
who were both smokers and rare allele carriers compared with smokers without the 
rare allele (32.9% vs. 23.4%).  
In the original GWAS, no association between rs4972593 and ESRD was seen in men 
when non-smokers and smokers were pooled (189). However, based on the findings of 
Study III, rs4972593 has a protective effect in men that is only seen in non-smokers. 
Non-smoking men who carry the rare allele had a 50% lower risk of ESRD compared 
with non-smoking men without the rare allele. No protective effect was found in 
smoking men who carried the rare allele. Smoking is a strong risk factor for the 
development of ESRD, and therefore the effect, either positive or negative, of 
rs4972593 might not be detected in smokers. However, it is also possible that smoking 
acts directly through epigenetic mechanisms and changes the risk profile of the 
genotype. This could explain why the protective effect of rs4972593 was not seen in 
smoking men.  
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The possible biochemical mechanism behind the association of rs4972593 and the 
modified risk of ESRD was elucidated in the earlier FinnDiane GWAS study (189). The 
location of this SNP is in the intergenic region between genes SP3 and CDCA7. Of these 
genes, only SP3 is expressed in the kidneys, and therefore the effect of rs4972593 is 
probably mediated through the SP3 gene. SP3 codes the transcription factor Sp3 that 
binds to estrogen receptor alpha (ERα) and forms a protein complex that regulates 
gene expression (351, 352). Based on animal models, estradiol action through ERα plays 
an important role in the development of chronic kidney disease. In female mice, the 
kidneys express the third largest number of estradiol-regulated genes after the uterus 
and pituitary gland, and the expression of these genes is regulated by ERα (353). Female 
ERα knock-out mice develop a form of chronic kidney disease probably due to elevated 
testosterone levels. However, the male knock-out mice do not develop kidney disease, 
despite elevated testosterone levels (354). In addition, in people with type 1 diabetes, 
changes in the testosterone levels are associated with the development of diabetic 
kidney disease, and an increase in testosterone is observed in men who have developed 
ESRD (355). The effect of testosterone via the androgen receptor is also mediated 
through the Sp1/Sp3 transcriptional network. Therefore, a disturbance in this signaling 
pathway could lead to a decreased effect of testosterone in male kidneys and 
eventually to a more beneficial outcome. Experimental studies have shown that the 
majority of estrogen receptors in the male kidneys consist of ERβ, whereas in the 
female kidneys the majority are of type ERα (356). Therefore, the gender differences 
seen in Study III could be explained by the more important role of estrogen and ERα in 
the development of ESRD in women compared with men. 
 
7.5 Current smoking and the risk of coronary heart disease, heart failure, 
and stroke 
 
Study IV showed a 30% higher risk of CHD in current smokers compared with never 
smokers. The association was stronger when smoking was assessed as intensity of 
smoking in packs per day or as cumulative smoking in pack-years instead of the 
traditional simple smoking status. The risk of heart failure was also higher in current 
smokers compared with never smokers, but when the lipid variables were included in 
the analysis the results were attenuated and the difference no longer significant. 
However, the trend towards a higher risk of heart failure was similar to that seen in the 
risk of CHD. 
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In the EURODIAB study, the risk of CHD in current smokers was similar to the risk in 
Study IV, although it was not statistically significant (78). In Study IV, when simple 
smoking status was used to group the participants, the risk in current smokers was 
similar to that in never smokers after adjustments for the lipid variables. The results in 
Study IV regarding the risk of heart failure in current smokers were in line with results 
based on data from the Swedish National Diabetes Register, although it combined 
current and former smokers (276).   
To our knowledge, no previous studies have reported results regarding the effect of 
both intensity of smoking and cumulative smoking on the risk of different CVD 
outcomes in people with type 1 diabetes. In studies of the general population, the 
increased risk of CHD associated with current smoking is around 3 times higher 
compared with the risk seen in Study IV (357). However, this does not indicate that 
smoking is less harmful for people with diabetes. It is of note that all people with 
diabetes, regardless of smoking status, already have a 3–5-fold increased risk of CHD 
that will likely dilute the effect of smoking in a study including only people with 
diabetes.  
Based on Study IV, smoking seems to have the strongest effect on the risk of stroke in 
people with diabetes, particularly in men. The risk of any stroke was doubled in men 
who were current smokers compared with never smokers. In the analysis including 
smoking intensity in packs per day and cumulative smoking in pack-years, the effect of 
smoking was more harmful on the risk of stroke compared with the risk of CHD or heart 
failure. Current smoking was not associated with a higher risk of stroke in women. 
However, in the general population smoking is shown to be equally harmful for men 
and women (270). The lack of a stronger association between smoking and the risk of 
stroke in women with diabetes could be explained by the fact that the excess risk of 
stroke associated with diabetes is around 30% higher in women than in men (177). 
Women also smoke less, and therefore the risk in all current smokers combined would 
presumably be lower. It is of note that there was no interaction between sex and 
smoking intensity or cumulative smoking in current smokers. This would indicate that 
the effect of smoking intensity and cumulative smoking is similar in men and women 
and that higher intensity or a cumulative dose is also harmful for women.   
Previous studies have often combined the risk of different CVD outcomes, and only a 
few have reported results regarding the association between smoking and the risk of 
stroke in people with type 1 diabetes. In the WHO multinational study of vascular 
disease smoking was not a significant risk factor for stroke (274). This might be due to 
the lack of power in their study, as the number of stroke events among people with 
type 1 diabetes who were current smokers was low, 24 in men and 9 in women, 
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compared with 63 and 27 in Study IV. However, the trend in their results for the risk of 
stroke was similar to the results of Study IV regarding men who were current smokers.   
 
7.6 Smoking cessation and the risk of diabetic nephropathy, coronary 
heart disease, heart failure, and stroke 
 
The risk of diabetic nephropathy in former smokers was assessed using several 
different approaches. When all former smokers were combined in one group, the risk 
of any diabetic nephropathy or ESRD was not significantly higher compared with never 
smokers. However, in the analyses including pack-year data, the risk of 
microalbuminuria increased in former smokers by 3.4% per each smoked pack-year. 
The risk of macroalbuminuria and ESRD was also similar compared with never smokers 
in the analyses with cumulative smoking data. The higher microalbuminuria risk could 
be explained by the definition of microalbuminuria, which included three UAER values 
above the threshold. Some participants might have already stopped smoking before 
the first urine sample was above the normal limit, and if this happened before the 
baseline visit the participant was classified as a former smoker. Participants with one 
or two higher UAER values are clearly at higher risk of microalbuminuria compared with 
those with only normal UAER values. However, smoking cessation was beneficial 
regarding the further progression of microalbuminuria to macroalbuminuria or ESRD. 
This was also seen when former smokers were grouped according to the number of 
years they had not been smoking before the baseline visit. If former smokers had 
stopped smoking less than 5 years before the baseline visit, their risk was equal to the 
risk seen in current smokers. After 5–10 years, the risk gradually decreased to the same 
level as in never smokers. 
Based on Study IV, the risk of CHD was similar in former smokers compared with never 
smokers when the association with simple smoking status was analyzed. However, we 
could observe a trend towards a higher risk in former smokers with a history of heavier 
smoking intensity, one pack of cigarettes more more per day. This was not the case in 
former smokers who had a history of heavier cumulative smoking or for the groups of 
former smokers who had smoked <20 or ≥20 pack-years, as they both had a similar risk 
of CHD as never smokers. In addition, if former smokers had an otherwise similar risk 
factor profile regarding glucose control, duration of diabetes, blood pressure, and lipids 
as never smokers, the risk of CHD did not differ from that for never smokers. These 
results are in line with those of the large EURODIAB study that reported a similar CHD 
risk in former and never smokers (78). Klein et al. reported a higher risk of myocardial 
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infarction in former smokers compared with never smokers, but they did not include 
the important risk factors of duration of diabetes, BMI, and lipids in their analysis (210).  
The heart failure risk in Study IV was around 30% higher in former smokers compared 
with never smokers. This was especially seen in the analysis addressing the association 
between cumulative smoking and the risk of heart failure, and the risk increase was still 
significant after adjustments for the lipid variables. To our knowledge, this was the first 
study to report results regarding the association between former smoking and heart 
failure in people with type 1 diabetes. The very few previous studies did not report their 
results separately for former smokers, and in the study from the Swedish National 
Diabetes Register, current and former smokers were combined (276, 277). 
In men, the risk of stroke remains twice as high compared with never smokers, even 
after smoking cessation. This risk was also higher after adjustments for other known 
CVD risk factors. This indicates that even though the CHD risk seems to decrease after 
smoking cessation, former smokers with type 1 diabetes are still at extremely high risk 
of CVD outcomes. In women, the risk of stroke did not differ between the former and 
never smokers. However, this should not be interpreted in such a way that the risk 
would be low in women who have stopped smoking. In fact, the risk of stroke is high in 
all women with type 1 diabetes, and former or current smoking does not change the 
risk significantly, partly because the smoking exposure in women is lower than in men 
(177). In the WHO multinational study of vascular disease, the risk of stroke was not 
increased in former smokers, men or women (274). This is in line with the Study IV 
results for women. As discussed previously, that study only had a small number of 
stroke events in former smokers, 8 in men and 5 in women. In Study IV, every single 
stroke event, including those that occurred after the CHD or heart failure outcomes, 
was registered. Therefore, the number of stroke events in Study IV is clearly higher, 
which might explain the differences in the results. 
 
7.7 Study design, strengths, and weaknesses 
 
One of the major strengths in Study I–Study IV is the large number of study participants 
and the precise information regarding alcohol consumption and smoking habits. 
Compared with the EURODIAB study regarding alcohol consumption and the risk of 
microvascular complications, the number of diabetic nephropathy and severe diabetic 
retinopathy cases was 4 times higher in Study I (332). The risk of diabetic nephropathy 
and severe diabetic retinopathy in former consumers of alcohol was evaluated 
separately, and thereby the “sick quitter” effect among abstainers was avoided. The 
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EURODIAB study also reported results regarding diabetic neuropathy, information that 
is not included in Study I. However, the specific effect of alcohol on diabetic neuropathy 
is difficult to assess given the fact that alcohol consumption is also an important cause 
of neuropathy in people without diabetes. Interpretation of the results of Study I is 
limited because of the cross-sectional nature of the study. The exact timeline for 
alcohol drinking in former consumers was also not available, and therefore it remains 
unknown if they changed their drinking pattern before or after the microvascular 
complication was diagnosed. However, the results regarding abstainers are more 
reliable in Study I compared with studies that have combined former drinkers and life-
long abstainers. Binge drinking is associated with different vascular complications, and 
therefore information regarding drinking pattern might have elucidated the differences 
in the risk of diabetic nephropathy and severe diabetic retinopathy between consumers 
of different types of beverage. 
Compared with previous studies on the association between smoking and vascular 
complications in people with type 1 diabetes, Study II and Study IV included a larger 
number of study participants and a longer follow-up time. In addition, most of the 
previous CVD studies only reported the results for CVD mortality or for the combined 
risk of any CVD. However, Study IV provides exact information regarding the effect of 
smoking on CHD, heart failure and stroke. Most of the previous studies reported results 
for never smokers compared with ever smokers, which in fact represents a combination 
of former and current smokers. Therefore, Study II and Study IV give valuable 
information about the risk of diabetic nephropathy and different CVD outcomes in 
former smokers.   
The information about the participants’ alcohol consumption and smoking habits was 
based on self-reported questionnaires, and no confirmative laboratory measurements, 
such as carbohydrate-deficient transferrin or phosphatidylethanol for alcohol 
consumption or serum or urine cotinine levels for smoking, were performed. However, 
based on previous observations, self-reported questionnaires give reliable estimates of 
alcohol intake for participants in epidemiological studies (358). In addition, smoking 
prevalence is more likely to be underestimated based on the questionnaire data, and 
therefore the effect of smoking would be underestimated rather than overestimated 
(359). The smoking data for Study IV were also revisited based on data from prospective 
visits and a follow-up questionnaire that was mailed to all FinnDiane participants in 
2015. It is of note that the number of participants with incorrect baseline smoking data 
was low, and this information had to be corrected for only 46 participants. Exposure to 
passive smoking was not addressed in the questionnaire. This could have affected the 
results but mainly by increasing the risk of diabetic nephropathy or CVD risk in never 
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smokers, leading to a diminished difference between never smokers and current or 
former smokers. 
Despite the additional information from the prospective visits and from the follow-up 
questionnaire, there was no access to exact data regarding smoking habits after the 
baseline visit and before each vascular event. Therefore, the effect of time-varying 
exposure to smoking during the follow-up was not taken into account. However, Study 
II and Study IV included excellent data regarding smoking habits before the baseline 
visit, and compared with previous studies, Study II and Study IV provide more precise 
data regarding the effect of intensity of smoking and cumulative smoking on the risk of 
vascular complications in people with type 1 diabetes. 
To ensure correct alcohol and smoking data, participants with unclear information 
were excluded from the analyses. This might have affected the findings of Study I, as 
579 (13.8%) participants were excluded due a to lack of alcohol consumption data. 
However, clearly, fewer participants were excluded due to lack of smoking data, namely 
293 (7.5%) participants in Study II and 261 (5.5%) participants in Study IV. Only a few 
participants were excluded from the analysis because of unclear follow-up data 
regarding ESRD (4 participants) or CVD (4 participants) diagnoses. In Study II, Study III 
and Study IV, the diagnoses for ESRD and CVD outcomes were mainly based on register 
data from the Finnish Care Register for Health Care and the Cause of Death Register. In 
this study, only some ESRD diagnoses were collected from the medical records. 
However, register data regarding CHD has been verified previously in another 
FinnDiane study, and no classification errors were found (105).   
 
7.8 Mechanisms behind the effect of smoking on vascular complications 
in people with diabetes 
 
Cigarette smoke includes over 4000 possible harmful substances, and smoking affects 
the vasculature through multiple different pathways. Therefore, it is difficult to 
measure the independent effect of smoking on different vascular complications. In 
FinnDiane study population, current smokers had poorer glycemic control and a more 
atherosclerotic lipid profile with higher total cholesterol, triglycerides, and LDL 
cholesterol and lower HDL cholesterol. Generally, in CVD studies different risk factors 
are usually considered confounding factors. This is reasonable when, for example the 
association between a vascular complication and blood pressure is studied and the 
results are standardized for total cholesterol because high blood pressure does not 
directly elevate cholesterol values. However, regarding the associations between 
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smoking and different vascular complications, the results are more difficult to interpret. 
Based on the results of Study II and Study IV regarding the risk of diabetic nephropathy, 
CHD, heart failure, and stroke, the risk of any complication in question was increased 
in current smokers. However, after the results were adjusted for different lipid 
variables the increased risk was attenuated, and in some analyses the difference was 
no longer significant. Should this indicate that smoking is not a risk factor for those 
complications? A more likely scenario is that a part of the risk associated with smoking 
is actually mediated through the lipids. 
In studies regarding risk factors for vascular complications in people with type 1 
diabetes, the strongest risk factors are often other micro- or macrovascular 
complications. In Study IV regarding the risk of CHD, heart failure, and stroke, the effect 
of smoking was no longer significant after the results were adjusted for diabetic 
nephropathy. However, Study II showed that smoking increases the risk of any 
progression of diabetic nephropathy. Therefore, the fact that the effect of smoking on 
the risk of CVD is diluted when the results are adjusted for diabetic nephropathy does 
not indicate that smoking is a weaker risk factor for CVD. Instead, diabetic nephropathy 
could also be considered one of the mediating factors of the harmful effects of smoking.   
Many other studies of people with type 1 diabetes have not been able to show 
significant associations between smoking and different vascular complications. 
Compared with Study II and Study IV, some of these studies were smaller and had 
shorter follow-up time. Many studies have also defined smokers differently by 
combining current and former smokers. They have also lacked the more accurate 
measures of intensity or cumulative smoking. In these studies, as well as in Study II and 
Study IV, the effect of smoking is decreased in the analyses combining many other risk 
factors. Indeed, if these risk factors are only interpreted as confounding factors the risk 
of smoking is hard to distinguish, especially in a smaller study population. However, if 
some of these risk factors, such as lipids, glucose control, and diabetic nephropathy, 
are interpreted as mediating factors, the overall risk associated with smoking is higher 
than the risk estimates would indicate, and smoking would actually be an even more 







8 SUMMARY AND CONCLUSIONS 
 
I People who have stopped their alcohol consumption have the highest 
risk of diabetic nephropathy and severe diabetic retinopathy. In 
addition, abstainers have a higher risk compared with people who are 
consuming alcohol. Compared with drinking wine, drinking spirits is 
associated with a higher risk of diabetic nephropathy in men and a 
higher risk of severe diabetic retinopathy in both sexes. 
II Current smoking increases the risk of diabetic nephropathy, and the risk 
increases with the cumulative dose of smoking in pack-years. In former 
smokers, the risk of diabetic nephropathy is similar to that for never 
smokers as long as other risk factors are similar. 
III In women, the SNP rs4972593 is a risk factor for ESRD comparable with 
smoking, but in non-smoking men the rs4972593 has a protective effect 
regarding the risk of ESRD.  
IV Current smoking is associated with a higher risk of CHD and heart failure, 
particularly with higher cumulative smoking, and higher intensity of 
smoking. The risk of heart failure is increased in former smokers. In men, 
the risk of stroke is doubled in both current and former smokers 
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